Selective Bias Virtual Screening for Discovery of Promising Antimalarial Candidates targeting Plasmodium N-Myristoyltransferase

Selective Bias Virtual Screening for Discovery of Promising Antimalarial Candidates targeting Plasmodium N-Myristoyltransferase | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article Selective Bias Virtual Screening for Discovery of Promising Antimalarial Candidates targeting Plasmodium N-Myristoyltransferase Carolina Andrade, Bruna Katiele de Paula Sousa, Sunniva Sigurdardóttir, and 11 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-3963523/v1 This work is licensed under a CC BY 4.0 License Status: Under Review Version 1 posted You are reading this latest preprint version Abstract Malaria remains a significant public health challenge, with Plasmodium vivax being the species responsible for the most prevalent form of the disease. Given the limited therapeutic options available, the search for new antimalarials against P. vivax is urgent. This study aims to identify new inhibitors for P. vivax N -myristoyltransferase (PvNMT), an essential drug target against malaria. Through a validated virtual screening campaign, we prioritized 23 candidates for further testing. In the yeast NMT system, seven compounds exhibit a potential inhibitor phenotype. In vitro antimalarial phenotypic assays confirmed the activity of four candidates while demonstrating an absence of cytotoxicity. Enzymatic assays reveal LabMol-394 as the most promising inhibitor, displaying selectivity against the parasite and a strong correlation within the yeast system. Furthermore, molecular dynamics simulations shed some light into its binding mode. This study constitutes a substantial contribution to the exploration of a selective quinoline scaffold and provides valuable insights into the development of new antimalarial candidates. Biological sciences/Drug discovery/Medicinal chemistry/Structure-based drug design Biological sciences/Chemical biology/Computational chemistry Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 Figure 7 Introduction Malaria is a disease caused by protozoa of the Plasmodium genus, specifically the species P. falciparum and P. vivax 1 that cause the highest rates of mortality and morbidity, respectively. In 2022, global estimates surpassed 200 million cases, resulting in over 600 thousand deaths 2 . Vivax malaria, the most geographically widespread form of the disease, is predominantly found in tropical and subtropical regions. Cases caused by P. vivax account for approximately 72% of all malaria episodes occurring outside the African continent 3 . Notably, around 73% of reported cases in the Americas are concentrated in Venezuela, Brazil and Colombia 2 , 4 . P. vivax is biologically distinct from P. falciparum primarily due to the formation of hypnozoites, a latent stage that persists in the liver, posing a challenge for treatment due to the relapse episodes 5 – 8 . Additionally, P. vivax is characterized by its preference for reticulocyte infection 9 , 10 and the early production of sexual stages (gametocytes) observed in peripheral blood 11 , 12 . An additional concern is related to the growing resistance of P. vivax to chloroquine 13 – 15 . Despite being a frontline treatment for vivax malaria since 1946, current evidence shows the circulation of resistant strains in endemic areas across various continents, including the Americas 16 . Evaluating drug resistance in P. vivax is particularly challenging due to the difficulties in in vitro culturing of the parasite. Distinguishing between treatment resistance and late relapses identified in in vivo assessments adds complexity to the analysis 17 . Given these challenges, there is a pressing need to explore new therapeutic options for P. vivax . The N - myristoyltransferase protein (NMT) plays a crucial role in catalyzing the transfer of the fatty acid myristate (C14) from the myristoyl-CoA molecule to the N -terminal glycine residue of numerous proteins 18 . In humans, this protein exhibits two isoforms, attracting attention in cancer research as important targets for cell survival 19 . In contrast, in various organisms, such as Candida albicans 20 , Trypanossoma spp. 21 , 22 , Leishmania donovani 23 , 24 , Cryptosporidium parvum 25 , and Plasmodium spp. 26 – 28 , which express a single isoform of the protein, NMT stands out as a promising drug target. This has prompted extensive research to discover new therapeutic agents for diseases associated with these organisms 29 . Studies revealed that many Plasmodium proteins need this post-translational modification during various life stages of the parasite 28 , which is important for drug development of inhibitors. While inhibitors for Plasmodium NMT are currently described, achieving parasite selectivity remains a challenge. Efforts are underway to enhance the selectivity of these inhibitors for more effective targeting of the parasite. Structural studies revealed that the Plasmodium NMT enzyme is capable of forming an alternate conformation in the peptide binding pocket which preferentially binds some inhibitors compared to the human enzymes thus providing a rational hypothesis for how to achieve selectivity 30 . Structural studies of these selective hits support the identification of a distinct conformation of the Plasmodium enzyme which binds compounds preferentially compared to the human NMTs 25 , 31 . In this study (Fig. 1 ), we employed structural analysis and virtual screening of millions of commercially available compounds using validated, robust, and predictive computational models as filters. This process enabled us to select 23 candidates for subsequent in vitro evaluation. Our approach involved experimental testing within a developed NMT yeast system, followed by P. falciparum in vitro phenotypic and cytotoxicity assays. Subsequently, the selected candidates underwent evaluation against NMT enzyme. To deepen our understanding, molecular dynamics simulations were conducted to elucidate the binding mode of the most promising candidates. Through this synergistic integration of computational models and experimental evaluation, we successfully identified LabMol-394 as a promising compound targeting the translational process of malaria parasites. Results In silico studies Five high-affinity representative binding sites identified through structural analysis. Utilizing data from PDB ( https://www.rcsb.org/ ) , we collected 59 structures of NMT from H. sapiens (isoforms 1 and 2) and P. vivax . To conduct structural analysis using the Bio3D R package, we filtered the crystals based on the presence of a ligand, absence of mutations, and high resolution (≤ 2 Å), resulting in a total of 30 structures (10 for H. sapiens and 20 for P. vivax ). This comprehensive analysis involved aligning these structures followed by principal component analysis (PCA) to categorize similar conformations into clusters. Notably, our findings revealed distinct binding modes between Plasmodium compared to H. sapiens (Fig. 2 a). Building upon this insight, we focused on Plasmodium structures, identifying five clusters showcasing variations in conformation and ligand binding (Fig. 2 b). Subsequently, we selected the most representative structures based on inhibition (Ki or IC 50 ) from PDB IDs: 2YND, 2YNE, 4CAF, 4UFX and 6MB1. These structures served as the foundation for developing and validating both shape-based models and docking protocols. Validation of PvNMT Shape-based models The selected representative structures were employed to construct and validate shape-based models, as depicted in Fig. 3 . Notably, the application of RefTverskyCombo score yielded area under the curve (AUC) values ranging from 0.69 to 0.86 across all models. Particularly, the model generated using query PDB ID 2YNE demonstrated the highest performance, achieving an AUC of 0.86, along with an Enrichment Factor (EF) of 7.76 and BEDROC (Boltzmann-Enhanced Discrimination of ROC) score of 0.75 at the top 10%. These findings, summarized in Table 1 , provide compelling evidence for the efficacy of the best-performing shape-based model, which exhibits satisfactory metrics and hence serves as a reliable filter in the virtual screening process. Table 1 Validation of shape-based models employing different queries and RefTverskyCombo score. Queries AUC TOP 1% TOP 5% TOP 10% EF BEDROC EF BEDROC EF BEDROC 2YND 0.77 5.66 0.21 4.48 0.23 3.28 0.29 2YNE* 0.86 37.00 0.88 17.63 0.74 7.76 0.75 4CAF 0.73 1.49 0.08 3.58 0.13 3.13 0.21 4UFX 0.84 23.88 0.65 14.93 0.68 7.61 0.72 6MB1 0.69 7.46 0.20 3.88 0.19 2.09 0.22 AUC: Area under the ROC curve; EF: Enrichment Factor; BEDROC: Boltzmann-Enhanced Discrimination of ROC. *Selected model. Selective bias docking and post -processing with MMGBSA correlates with PvNMT activity To ensure the reliability of the docking program, validation was conducted using a prepared dataset of inhibitors and decoys along with the crystal structure of PvNMT PDB ID 2YNE, derived from the best-performing shape-based model. The results obtained from the top 10% of the ranked list yielded metrics including an AUC of 0.863, EF of 6.62 and a BEDROC of 0.65, all of which were considered satisfactory, validating the utilization of the Glide program for docking purposes. Subsequent redocking procedure involving the ligand at PDB ID 2YNE (2-(3-piperidin-4-yloxy-1-benzothiophen-2-yl)-5-[(1,3,5-trimethylpyrazol-4-yl) methyl]-1,3,4-oxadiazole), and its interaction with Plasmodium and human isoforms (I and II), revealed several key binding interactions. In P. vivax , the inhibitor primarily engages in π-stacking interactions with Phe105 and Tyr211, while also forming a hydrogen bond mediated by a water molecule with Ser319, and establishing a donor-salt bridge interaction between the piperidine ring and Leu410. This interaction yielded a docking score of -12.66 Kcal/mol and a predicted MMGBSA-ΔG of -99.37 Kcal/mol. Similarly, when interacting with HsNMT-1, the ligand engages in π-stacking interactions with tyrosines 296 and 420, forms a hydrogen bond with Ser405 (equivalent to Ser319 in P. vivax ), and establishes a salt bridge interaction with Gln496 (analogous to Leu410 in P. vivax ). This interaction resulted in a docking score of -10.81 Kcal/mol and a significant predicted MMGBSA-ΔG difference of -28.60 Kcal/mol. Conversely, when interacting with HsNMT-2, the docking results suggested predominantly hydrophobic interactions at the peptide binding site, resulting in a docking score of -3.63 Kcal/mol and an MMGBSA-ΔG of -27.42 Kcal/mol. These findings are consistent with the IC 50 for this ligand against human isoform 1 (60 ± 3 nM), demonstrating potential selectivity against Plasmodium (see Supplementary file, Fig. S1 ). Furthermore, we evaluated the correlation between pK i values and the predicted docking scores and MMGBSA values by calculating the correlation coefficient. Visual inspection of the data (see Supplementary file, Fig. S2 ) reveals that the most potent compounds exhibit docking score and MMGBSA values lower than − 11 Kcal/mol and − 80 Kcal/mol, respectively. Therefore, based on the docking metrics, redocking results and MMGBSA post -processing values obtained, we concluded that the program effectively predicts values closely aligned with the activity of the most potent compounds in the PvNMT dataset. Virtual Screening prioritizes 23 potential hits With the models duly validated, the virtual screening was conducted applying the following filters (Fig. 4 ): Utilization of the best molecular shape-based model for PvNMT, where the top 10% (131,982 compounds) of the list progressed to filter 2 for subsequent docking and selective rescoring between P. vivax and human isoforms. Examination of the top 10% of the list based on the MMGBSA-ΔG score (≤ -70 kcal/mol). Compounds demonstrating a difference of ≤ -50 kcal/mol between HsNMT isoforms were singled out, resulting in the selection of 290 compounds. Application of P. falciparum 3D7 (mandatory) and W2 classificatory QSAR models to predict the activity of compounds selected in the previous step (80 compounds), given the importance of the target in asexual blood stages. Implementation of cluster analysis to identify representative chemotypes. Additionally, analysis of MMGBSA poses and evaluation of predicted ADMET characteristics were conducted. This comprehensive approach led to the final selection of 23 compounds (see Supplementary file, Table 1 ). Experimental evaluation NMT yeast-based system for identification of potential inhibitors We used a modified yeast strains system expressing the NMT targets of both H. sapiens and P. vivax that allows a fast and cost-effective identification of potential selective inhibitors and cytotoxic compounds. Cells were cultivated and subjected to tests at 100 µM in triplicate for each strain (yPvNMT, yHsNMT1 and ScNMT). Optical density (OD) was measured over a 72-hour period. In this assay, compound inhibition is determined by the reduction in growth rate compared to the control (180 µL of cells and 20 µL of YPD medium) in the presence of compound. As a result, seven compounds (Fig. 5 ) presented an inhibition phenotype, with some demonstrating a degree of selectivity against the strain expressing P. vivax NMT strain, as evidenced by a reduction in growth ratio (yield) compared to the human strain. Notably, LabMol-394 exhibited a vivax phenotype, indicating potential selectivity towards the parasite isoform. Four compounds exhibited antimalarial activity To evaluate the antimalarial activity of the compounds, we conducted tests against chloroquine-sensitive Pf 3D7 and drug-resistant Pf Dd2 and Pf SB1A6 strains, using a concentration of 5 µM, as detailed in Table 2 . Initially, we determined the percentage of parasite growth inhibition and subsequently generated dose-response (EC 50 ) curves. Four compounds, LabMol-392, LabMol-393, LabMol-394, and LabMol-395, exhibited inhibition exceeding 80% against 3D7 strain parasites (see Supplementary file, Fig. S3 and S4), with EC 50 values ranging from 0.098 to 1.10 µM. Notably, all compounds tested exhibited low cytotoxicity, as evidenced by the selective index (the ratio of selectivity to the parasite over mammalian cells) higher than 10 (except for LabMol 393), aligning with guidelines for malaria drug development 32 . Furthermore, hemolysis tests were conducted at a maximum concentration of 20 µM indicated no hemolytic activity for any of the compounds tested (Supplementary file, Fig. S5). The most promising compound identified in the phenotypic screening is LabMol 395, demonstrating potent antimalarial activity below 0.17 µM against all three P. falciparum strains tested herein. Moreover, it exhibits remarkable selectivity for the parasite over mammalian cells (SI > 10), indicating significant potential for advancement in pre-clinical studies. NMT enzymatic assays revealed potential inhibitors We conducted a two-point NMT inhibition assay of the top 23 potential inhibitors. Activity percentages were determined at 2 µM and 20 µM to identify a potential activity of compounds. Unfortunately, IC 50 calculations were not feasible due to compound solubility limitations. Nevertheless, the two-point enzymatic screen identified four promising compounds – LabMol-391, LabMol-392, LabMol-393 and LabMol-394 – which exhibited a minimum of 52% decrease in enzyme activity at a concentration of 20 µM against PvNMT (See Fig. 6 ). Regrettably, dose-response curves for the identified hits were hindered by compound precipitation at concentrations exceeding 40 µM. Subsequently, all compounds showing decreased activity were also tested against the human enzyme (HsNMT) in dose response studies ranging from 40 to 0.160 µM. Importantly, none of the compounds demonstrated inhibition of the human orthologue (HsNMT > 40 µM, see Supplementary file, figures S6 and S7). These findings highlight four hit compounds that selectively inhibit PvNMT over HsNMT, thereby validating the efficacy of our computational selectivity approach. Molecular dynamics simulations to analyze the binding mode of LabMol-394 Molecular dynamics simulations of 300 nanoseconds were conducted to evaluate the stability and binding dynamics of LabMol-394 with PvNMT. During this simulation, several significant interactions were observed. Although LabMol-394 (Fig. 7 ) does not directly engage with a critical residue, Leu410, it consistently maintains π-stacking interactions with residues Tyr211 and Phe105, occurring approximately 51% and 63% of the time, respectively. Intriguingly, a persistent hydrogen bond with Ser387 and the hydroxyl group was observed for approximately 34% of the simulation duration, while a π-cation interaction with Tyr211 and nitrogen of the pyridine ring was maintained for approximately 51% of the time. Discussion The process of discovering compounds with biological activity is a significant challenge, demanding the application of robust and predictive methodologies to ensure reliable outcomes. Bioinformatics and cheminformatics analyses serve as foundational tools in the search for novel antimalarial agents. Their effectiveness is evident through validation and research efforts led by esteemed organizations such as MalDA, MMV, the Bill and Melinda Gates Foundation, and the pharmaceutical industry 33 . A crucial aspect of antimalarial drug discovery involves the identification of novel targets essential to the parasite’s life cycle and conserved among various Plasmodium species. This strategy aims to encompass species previously overlooked as harmful to humans 34 . Consequently, the integration of computational strategies plays a crucial role in the discovery process, enabling the exploration of innovative mechanisms of action for potential new antimalarials. The NMT enzyme was validated as a target for antimalarial drugs in 2014 30 with many inhibitors initially repurposed from other organisms 21 , 35 – 37 and through High Throughput Screening (HTS) campaigns 38 , 39 . The latest NMT inhibitors, highlighted by Rodríguez-Hernández and colleagues, particularly compounds 12b and 30a from the series of hybrids of DDD85646 30 and IMP-1002 40 PvNMT inhibitors studies, demonstrated significant potency in vitro against PvNMT, with IC 50 of 0.0368 µM and 0.089 µM, respectively. However, their efficacy against hypnozoites and schizonts was observed to be in the low micromolar range 31 . In our study, we initially conducted an analysis of structural conformations within a collection of crystal structures containing the new PvNMT inhibitor. This analysis allowed us to discern the various binding modes employed by the inhibitors. In parallel, a gathered set of compounds from the literature that had been tested against PvNMT, rigorously validating our shape-based and docking computational models, in accordance with established good practices 41 , 42 . Subsequently, a virtual screening campaign was conducted. Our approach involved utilizing a predicted ΔG difference between Plasmodium and human proteins as a filter to reevaluate the docking scores. This strategy enabled us to prioritize compounds that showed potential selectivity for the parasite. As a result, we identified and prioritized 23 compounds with promising characteristics for further investigation. During the experimental validation phase, seven compounds exhibited a phenotypic effect against the modified yeast NMT strains. Next, the compounds were assessed for their efficacy against P. falciparum strains, considering its significant identity (> 80%) of NMT between the species 43 . Notably, in P. falciparum strains assays, four of these compounds demonstrated significant activity against three parasite strains, all at a single concentration of 5 µM, without any indications of cross-resistance and no signs of cytotoxicity (< 50 µM) or hemolysis, which are indicative of a favorable chemical safety profile. It's important to consider that the observed micromolar activity against the parasites may be influenced by the compounds' permeability to erythrocytic cells. Moreover, various efflux pumps, such as mdr1 and mrp1 in Plasmodium , known for their role in resistance mechanisms 44 – 46 , could affect the activity of these compounds. In yeast cells, the primary efflux pump for drugs, the gene PDR5 , was deleted in the strains we used 47 . This deletion leads to an increase in the concentration of compounds inside the cells, potentially explaining the divergent results observed for some compounds. One standout compound from these assays, LabMol-395, displayed an antimalarial efficacy below 0.17 µM against P. falciparum strains examined. However, this particular compound did not exhibit a yeast phenotype against NMT, indicating that its antimalarial activity likely involves a different target. On enzymatic NMT assay, LabMol-394 exhibited modest activity, resulting in a 52% decrease in the activity of PvNMT at a concentration of 20 µM, displaying selectivity towards vivax over the human isoform. Molecular dynamics simulations revealed that LabMol-394 demonstrated interactions comparable to PvNMT inhibitors, including those used in the shape-based modeling. However, it lacked interaction with Ser319, previously suggested as a crucial residue in the proposed mechanism of NMT inhibition 30 . Throughout our simulations, LabMol-394 did not engage with a crucial residue, Leu410. However, it sustained significant π-stacking interactions with Tyr211 and Phe105 residues, while also forming a hydrogen bond with Ser387. Although Ser387 is not currently associated with inhibition in the literature, we hypothesize it as a potential mechanism. Chemically, LabMol-394 features a quinoline scaffold extensively documented for its diverse biological activities 48 . This scaffold is particularly renowned for its well-established antimalarial effects, primarily attributed to its inhibition of β-hematin and the formation of an irreversible complex with the heme group 49 . These actions disrupt the development of the parasite in both liver and red blood cells. Notably, recent reports unveiled a novel quinoline inhibitor targeting the translation elongation factor 2 (PfEF2), demonstrating multistage antimalarial properties and currently progressing through clinical stages 50 – 53 . This discovery underscores the significance of heterocycles as crucial sources of chemical activities and introduces new mechanisms of inhibition aimed at pivotal targets in the Plasmodium life cycle. The prioritized candidates in this study were experimentally validated and the results demonstrated a correlation between antimalarial activity and the absence of cytotoxicity. LabMol-395 emerged as promising candidate for target identification, due to its favorable antimalarial profile. Furthermore, enzymatic assays revealed LabMol-394 as the most promising PvNMT inhibitor, exhibiting selectivity against the parasite. Remarkably, there was a good correlation between the results obtained from the yeast system and enzymatic assays in NMT. This study makes a significant contribution to the exploration of the quinazoline scaffold, showcasing activity against Plasmodium vivax NMT and offering prospects for further optimization and development. Methods Computational Structural analysis For structural analysis, we utilized the Bio3D R package 54 , 55 , focusing on crystals with assigned ligand, no mutations and showed high resolution (≤ 2 Å). This analysis comprised the alignment of these structures and then principal component analysis (PCA) of the conformations was performed. Data collection and preparation To distinguish active compounds from inactive ones, we constructed and validated shape-based models. Initially, compounds tested against the enzymes of both P. falciparum and P. vivax were collected from the literature 24 , 35 , 56 – 59 . Subsequently, employing the protocol outlined by Fourches and colleagues 60 , 61 , we processed an initial set of 152 compounds. Briefly, the hydrogens were explicitly included while excluding counter ions, inorganic salts, polymers, mixtures, and organometallic compounds. We set a threshold for inhibitor activity considering compounds with Ki or IC 50 values ≤ 1 µM as active and those with values ≥ 1 µM, as inactives. Additionally, specific chemotypes, such as aromatic and nitro groups, were standardized and duplicates were analyzed following the criteria: (i) entries with identical reported outcomes were consolidated, keeping only one, while the redundant entry was eliminated, and (ii) if duplicates exhibited inconsistent biological activity, both entries were removed from the dataset. Subsequently, the final dataset includes 137 unique compounds, comprising 67 inhibitors and 70 non-inhibitors. To augment the chemical diversity of the dataset, we generated 36 decoys for each inhibitor. The dataset, including actives, inactives and decoys, underwent appropriated hydrogen protonation state on neutral pH (7.4) using the Open Babel program 62 . Subsequently, for each molecule, 200 conformers were generated using the OMEGA 63 program, and AM1BCC charges 64 , 65 were estimated using the QUACPAC software 66 . Validated shape-based models were then built using the ligand conformations extracted from the Protein Data Bank (PDB) and employed as queries at the ROCS v. 3.4.2.1 program 67 . Shape-based model development and validation To assess the predictive performance of the shape-based models, the following metrics were analyzed: Receiver Operating Characteristic (ROC) curve, which provides a graphical representation of the true positive rate (sensitivity) against the false positive rate (1-specificity); Area Under the ROC Curve (AUC), which quantifies the probability of an inhibitor being ranked higher than an inactive compound when compared to a random selection by the query 41 , 68 ; Boltzmann-Enhanced Discrimination of ROC (BEDROC), which uses an exponential decay function to assign weights to actives that ranked higher in the list 69 ; Enrichment Factor (EF), that evaluates the fraction of actives found at the Top n % of the ranking compared to a random selection 70 , 71 . The statistical metrics were calculated using the following equations: $$AUC= \sum i\left[\left({Se}_{i+1}\left)\right({Sp}_{i+1}-{Sp}_{i}\right)\right] \left(1\right)$$ $$BEDROC=RIE \frac{{R}_{\alpha }sin\left(\frac{\alpha }{2}\right) }{cosh\left(\frac{\alpha }{2}\right)-cosh\left(\frac{\alpha }{2-\alpha {R}_{\alpha }}\right)}+ \frac{1}{1-{e}^{\alpha \left(1-{R}_{\alpha }\right)}}\approx \frac{RIE}{\alpha }+ \frac{1}{1- {e}^{{\alpha }^{{\prime }}}} \left(2\right)$$ $$if \alpha {R}_{\alpha }\ll 1 and \alpha \ne 0$$ $${EF}^{x\%}= \frac{\raisebox{1ex}{${Hits}^{x\%}selected$}\!\left/ \!\raisebox{-1ex}{${N}^{x\%}selected$}\right. }{\raisebox{1ex}{${Hits}_{total}$}\!\left/ \!\raisebox{-1ex}{${N}_{total}$}\right.} \left(3\right)$$ Selective bias docking and post-processing with MMGBSA The protein structures of Plasmodium (PDB ID: 2YNE) 30 and H. sapiens (PDB ID: 5O6J) 72 were processed in the Protein Preparation Wizard module 73 within Maestro (Schrödinger 2021-4, http://www.schrodinger.com ). This protocol includes addition of hydrogen atoms, calculation of ionization states at physiological pH (7.4 ± 0.5) using the Epik program 74 , 75 , and removal of structural waters with a distance greater than 3 Å from the side chains. Subsequently, protein hydrogen bond assignments and protonation states were refined using PROPKA, followed by restrained minimization using the OPLS-2005 force field 76 , 77 . Ligand preparation was carried out in the LigPrep module in Maestro (Schrödinger 2021-4, http://www.schrodinger.com ) , with ionization states set at physiological pH (7.4 ± 0.5) using the Epik program. Conformers were generated, retaining the stereoisomerism, and the geometry was minimized using the OPLS-2005 force field. Three-dimensional coordinates of the grid were constructed using the Receptor Grid Generation (Schrödinger 2021-4, http://www.schrodinger.com ) module at the region of the peptide binding site reported in the literature for P. vivax 30 (grid coordinates x = 24,29, y = 43,20, z = 64,66) and H. sapiens 72 (grid coordinates x = -18,31, y = 4,55, z = -19,80), have a size of 10 Å. Docking validation was performed with the Glide program 78 (Schrödinger 2021-4, http://www.schrodinger.com ) using the PvNMT dataset prepared and protein structure of PvNMT. Standard precision (SP) was utilized, employing a score function that uses an exhaustive sampling search, recommended for virtual screenings campaigns 79 . Statistical metrics including AUC, EF and BEDROC were computed using an in-house workflow in KNIME 80 to assess the robustness of the docking program. The MMGBSA rescoring method was performed in the Prime module version 3.0 (Schrödinger 2021-4, http://www.schrodinger.com ). This module computes the energy of the ligand-protein complex in solvent from the initial docking poses. Rescoring was applied during protocol validation and during virtual screening for the Top 10% of the ranked list. The system was composed of implicit solvent of the VSGB2 model 81 , parametrized on OPLS-2005 force field. The hierarchical sampling method was employed, with active site residues kept rigid in the first cycle and site conformations explored in the second cycle until finding the lowest ΔG value expressed in Kcal/mol 82,83 . Virtual Screening Following the validation of shape-based models and docking, augmented by MMGBSA rescoring, the virtual screenings were carried out using the Core library and Express-Pick collection stock libraries from the ChemBridge database ( https://www.chembridge.com/screening_libraries/ ) and Life Chemicals Antimalarial Screening Libraries ( https://lifechemicals.com/screening-libraries/targeted-and-focused-screening-libraries/antimalarial-screening-libraries ). These combined libraries encompass over 1.5 million compounds in total. These data were compiled and processed following the mentioned protocol for ligand preparation. The first filter was the best shape-based model for PvNMT, where the Top 10% of the list went to the selective docking and rescoring filter between Plasmodium and human NMT. The Top 10% analyzed with the MMGBSA-ΔG threshold ≤ -70 Kcal/mol for PvNMT and presents a difference of ≤ -50 Kcal/mol against HsNMT. The compounds selected in the previous step were predicted by the 3D7 and W2 malaria machine learning models(described in 84 ), considering that the target is essential during the asexual blood stage. For the final selection process, cluster analysis was performed using DataWarrior software 85 to identify representative chemotypes and avoid redundancy by excluding very similar compounds. Additionally, a medicinal chemistry visual inspection of the MMGBSA pose was performed, and predictions of ADMET (Absorption, Availability, Metabolism, Excretion and Toxicology) were made using the SWISS-ADME server ( http://www.swissadme.ch/ ) 86 . Finally, the prioritized candidates (See Supplementary Data file 1) were purchased and validated through in vitro assays using yeast-modified strains expressing P. vivax and human NMT, as well as P. falciparum 3D7, Dd2 and SB1A6 strains, cytotoxicity and enzymatic assays to comprehensively evaluate the compounds' efficacy and safety profiles. Molecular Dynamics simulations The simulations were performed in the Desmond program version 6.9 87 on the Maestro platform (Schrödinger 2021-4, http://www.schrodinger.com ). The system for the 300 nanoseconds simulation was built in the System Builder module and used the explicit solvent (H2O) model of the TIP3P type 88 , 89 , the periodic boundary conditions of the orthorhombic type with water buffer at 10 Å around the protein. Ion’s sodium (Na + ) and chlorine (Cl − ) were added to neutralize the system, whose final concentration was NaCl at 150 mM. The system was minimized in a cubic box using the OPLS4 force field 90 and the isothermal-isobaric NPT ensemble was used, in which the number of particles, pressure and temperature in the system were constant. To adjust the temperature, the Nose-Hoover thermostat 91 at 300 K, and the Martyna-Tobias-Klein barostato 92 at 1.01325 pressure was used. Data processing of Root Mean Square Deviations (RMSD), Root Mean Square Fluctuation (RMSF), and protein-ligand interactions were obtained in the Simulation Interactions Diagram module. Trajectory cluster analysis was performed using the Trajectory clustering module on Maestro (Schrödinger 2021-4, http://www.schrodinger.com ) to obtain the most representative conformations of the lowest energy of the most populated cluster. Experimental Construction of plasmids and yeast -modified strains By codon usage optimization for expression in Saccharomyces cerevisiae , the coding sequences of NMT from H. sapiens and P. vivax (here referred to as HsNMT and PvNMT, respectively) were synthesized, amplified by PCR, and subsequently, cloned into the Bam HI- Pst I sites of the yeast expression vector pCM188-URA3 (EUROSCARF), resulting in the generation of the following constructs: pCM188-URA3-HsNMT and pCM188-URA3-PvNMT. For more details on these constructs, please review the publication from Bilsland, E. and colleagues 93 . The DNA constructs, verified by sequencing, were used in this work for the yeast-based functional complementation system. S. cerevisiae strains and plasmids used are listed in Table 3 . Table 3 Plasmids and strains used in this study. Plasmid Features Derived from Source pCM188-URA3 CEN ; URA3 ; TetO2 promoter - EUROSCARF pCM188-URA3-HsNMT Homo sapiens NMT pCM188-URA3 Ref 74 pCM188-URA3-PvNMT Plasmodium vivax NMT pCM188-URA3 Ref 74 BY4741 MATa his3∆1 leu2∆0 met15∆0 LYS2 ura3∆0 EUROSCARF nmt1∆/NMT1 nmt1::KanMX/NMT1 MATa/MATα his3∆1/his3∆1 leu2∆0/leu2∆0 met15∆0/MET15 LYS2/lys2∆0 ura3∆0/ura3∆0; Kan/G418 EUROSCARF nmt1∆/NMT1_p pdr5::HISMX/PDR5 nmt1::KanMX/NMT1 MATa/MATα his3∆1/his3∆1 leu2∆0/leu2∆0 met15∆0/MET15 LYS2/lys2∆0 ura3∆0/ura3∆0; Kan/G418 HISMX nmt1∆/NMT1 Ref 74 Phenotypic analysis using Bioscreen YPD media (20% glucose,2% peptone, and 1% yeast extract) was used for routine culturing of strains. Frozen stocks on exponential growth phase were transferred to Falcon tubes with YPD media. Growth was maintained for an hour in a rotary shaker at 30°C at 200 rpm. Before the start of experiment, the medium was removed, and the pellet resuspended in new media to a final OD 600 of 1.0. Subsequently the cultures were diluted to an OD 600 of 0.1 into 100-well honeycomb plates (Labsystems Oy) pre-aliquoted with the appropriate media and tests. Strains were cultivated for 3 days with the low shaking setting at 30°C with 20 minutes measurement intervals using a wide band filter (450 to 600 nm) using Bioscreen C (Labsystems Oy). At the end of the experiment, the data were treated and normalized in the PRECOG program 94 . Then an R script was used using a growth curve library, to compute the cell yield (K) values, which was the parameter that best fits the data 95 . The data was subsequently exported to the GraphPad Prism 9 program, and the growth of tests and control growth were analyzed by the non-linear logistic regression model. Phenotypic antimalarial assays The antimalarial activity assay was assessed on P. falciparum 3D7 (chloroquine-sensitive), Dd2 (chloroquine-resistant) and SB1 (atovaquone-resistant) strains 14 . The parasites were cultivated in RPMI 1640 medium (SIGMA-ALDRICH), supplemented with hypoxanthine 0.005%, glucose 0.2%, sodium bicarbonate 0.2%, O + red blood cells (RBCs) and A + human plasma 10%. The cultures were incubated at 37°C in a low oxygen environment (3% O2, 5% CO2, and 92% N2) as described by Trager et al. 96 Drug inhibition assays were performed as previously described 97 . Briefly, synchronizations with 5% D-Sorbitol solution were performed at 48-hour intervals before experiments to allow incubations with > 90% of the parasites in the ring stage. Assays were performed in a 96-well plate, with 0.5% parasitemia and 2% hematocrit, in the presence of 5 µM of compounds or the drug vehicle (DMSO), as a control. Artesunate was used as an antimalarial standard. After 72 hours of incubation, parasitemia was assessed by fluorometry using SybrGreen fluorescent dye 98 . The plates were read in a CLARIOStar plate reader (BGMtech) by fluorescence at 490 nm excitation and 540 nm emission wavelengths. The growth inhibition values were expressed as percentages relative to the drug-free control, and EC 50 values were calculated by plotting Log dosing vs growth inhibition (expressed as percentages relative to the drug-free control) using GraphPad Prism 8. The experiments were carried out in three independent assays. Hemolysis assay The hemolysis assay was carried out according to Wang et al. (2010) 99 with modifications. Suspensions of erythrocytes (2% hematocrit) were incubated with the compounds at 20 µM or the drug vehicle (DMSO), as a control, at 37°C, 5% CO 2 , for 4 hours. The reaction mixtures were centrifuged at 1000g for 5 minutes, and the absorbance of the supernatants was measured at 540 nm using a Biotek Synergy-HT spectrophotometer. The hemolytic rate was calculated in relation to the hemolysis of erythrocytes in 1% of Triton X100, which was taken as 100%, using GraphPad Prism 8. The experiments were carried out in triplicate, relative to two independent assays. Cytotoxicity assays The cytotoxicity was evaluated using the MTT (3-[4,5-dimethyl-thiazol-2-yl]-2,5-diphenyltetrazolium chloride) reduction assay for quantification of cellular reductase enzymes activity as an indirect measurement of cell viability using human hepatocarcinoma cell line (HepG-2) and fibroblast-like cell lines derived from monkey kidney tissue (COS-7 cells 100 ). Briefly, the cells were cultured in Dulbecco's Modified Eagle Medium supplemented with 10% heat-inactivated fetal bovine serum and 1% antibiotic-antimycotic solution (10,000 UI of penicillin, 10 mg of streptomycin in 0.9% sodium chloride; Sigma Chemical Co., Saint Louis, USA) at 37°C and 5% CO 2 . The assays were conducted in a 96-well plate at a density of 10 4 cells per well. The cells were then incubated with a serial dilution of the drugs, starting at 100 µM, along with non-treated controls, for 72 hours. After the drug treatment, MTT was added to the wells, and absorbance readings were obtained using a CLARIOStar plate reader (BGMtech) at a wavelength of 570 nm (OD570). Cellular viability was expressed as a percentage relative to the vehicle-treated control. The CC 50 was calculated by plotting a log dose vs. viability curve using GraphPad Prism 8. The experiments were performed in two independent assays. Enzymatic assays To measure the activity of the purified PvNMT, an activity assay was adapted from Goncalves et al, 2012 101 . A fresh stock of 4x assay buffer was made consisting of 9.2 mM potassium phosphate (KH 2 PO 4 ), 69.7 mM sodium phosphate (Na 2 HPO 4 ), 2 mM EDTA, and 0.04% TritonX-100 at pH 7.0. Fresh working stock solutions were made by adding DMSO for a final concentration of 1% or 5% and a concentration of 1x assay buffer. Another working stock solution was made by adding DMSO for a final concentration of 10%, without assay buffer. The test compound solutions were made from the 20 mM stock. The test compounds were diluted in 10% DMSO to make a 10mM stock. From the 10 mM stock, the test compounds were further diluted into 20 µM and 2 µM stocks in 10% DMSO. A 10 µM stock of a control inhibitor, known as Control 02(DDD85646), was made, and then further diluted in 10% DMSO to make a 2 µM solution. 10 µL of the test compounds were plated in triplicates in a black, closed bottom 96-well plate (Greiner Bio-One). For the negative and positive control, 10 µL of 10% DMSO was plated in quadruplicates. 10 µL of the control inhibitor, Control 02, was plated in quadruplicates. The PvNMT protein was diluted in 1% DMSO containing 1x assay buffer for a final concentration of 10 µM. The PvNMT protein was diluted further in 1% DMSO, and 50 µL was added to each well in the 96-well plate for a final PvNMT concentration of 25 nM. For the negative control, 50 µL of 1% DMSO containing 1x assay buffer was added to the well instead of the PvNMT protein. The reaction was initiated by adding 50 µL of reaction substrate containing 10 µM PfARF (Gly-Leu-Tyr-Val-Ser-Arg-Leu-Phe-Asn-Arg-Leu-Phe-Gln-Lys-Lys-NH2 purchased from Innopep in San Diego, California), 10 µM Myr-CoA (myristoyl coenzyme A purchased from purchased from Med Chem 101 LLC in Plymouth Meeting, Pennsylvania), and 8 µM CPM (7-Diethylamino-3-(4'-Maleimidylphenyl)-4-Methylcoumarin purchased from Thermo Scientific Life Technologies in Grand Island, New York) to each well. Fluorescent readings were immediately taken of the plate using Spectra M2 plate reader (Molecular Devices) with excitation at 385 nm and emission at 485 nm. Reading continuously were taken in one-minute intervals for 45 minutes. Background fluorescence and noise were determined by replacing each constituent of the reaction individually with 1% DMSO containing 1x assay buffer, and values were deducted from experimental samples. The percent inhibition of each test compound was calculated using Prism (GraphPad Software, Inc). Declarations Data availability The docked structures, MD simulation trajectories data are available as free download at 10.5281/zenodo.10477925 . Protein expression plasmids of Pv NMT and Hs NMT1 and Hs NMT2 are available at https://www.ssgcid.org/available-materials/ssgcid-proteins/ through material transfer agreement (MTA). All additional data are available from the corresponding authors on reasonable request. Acknowledgments BKPS was supported by fellowships from Brazilian agencies CNPq (process 142059/2020-0), and CAPES-STINT project number 88887.304810/2018-00. This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – Brasil (CAPES) – Finance Code 001. This work has been funded by CNPq BRICS STI COVID-19 (#441038/2020-4), FAPEG (#202010267000272), São Paulo Research Foundation (FAPESP grants #2020/06190-0, #2021/10084-3, #2021/13237-5 and #2020/05369-6). CHA and FTMC are CNPq research fellows. FTMC thanks the Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) grant numbers 2017/18611–7 and 2018/07007–4. LCS was funded by FAPESP (process 2023/07805-6). The authors thank the Swedish Research Council (VR), grant numbers 2019-3684 and 2021-03667, and the Swedish Foundation for International Cooperation in Research and Higher Education (STINT), grant number BR2018-8017. The computations were enabled by resources provided by the National Academic Infrastructure for Supercomputing in Sweden (NAISS) and the Swedish National Infrastructure for Computing (SNIC) at Tetralith and Vera supercomputers, partially funded by the Swedish Research Council through grant agreements no. 2022-06725 and no. 2018-05973. This project has been funded in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, to support the Seattle Structural Genomics Center for Infectious Disease (SSGCID) under Contract No. HHSN272201700059C. (BLS, SG, MK, RZ). Research reported in this publication was supported by the National Institute for Allergy and Infectious Disease of the National Institutes of Health under award number R01AI155536 (BLS). We are grateful to OpenEye Scientific Software Inc. (https:// www.eyesopen.com/) for providing academic license of their programs. Author contributions . Each author has contributed significantly to this work. BKPS conducted the in silico experiments, which involved developing shape-based models, docking models, conducting virtual screening, and performing molecular dynamics simulations. JVVB filtered compounds through the QSAR malaria models. BKPS and SSS performed the yeast-based assays. LCC and LCS performed the malaria phenotypic, hemolysis assay and cytotoxicity assays. RZ, MK and SG conducted the NMT enzymatic assays. BKPS drafted the manuscript and all authors contributed additions and corrections. CB, PS, LAE, FTCM, BS and CA revised the paper. All authors read, edited, and approved the final manuscript. Funding Open access funding provided by University of Gothenburg. Competing interests The authors declare no competing interests. Additional information Supplementary information: The online version contains supplementary materials available at link to be provided. References Phillips, M. A. et al. Malaria. Nat. Rev. Dis. Prim. 3 , 17050 (2017). Organização Mundial da Saúde. World Malaria Report 2023. World Health WHO/HTM/GM, 238 (2023). Howes, R. E. et al. Global epidemiology of Plasmodium vivax. Am. J. Trop. Med. Hyg. 95 , 15–34 (2016). Ministério da Saúde. Secretaria de Vigilância em Saúde.Brasil. Boletim Epidemiológico. 55 , (2024). Mikolajczak, S. A. et al. Plasmodium vivax liver stage development and hypnozoite persistence in human liver-chimeric mice. Cell Host Microbe 17 , 526–535 (2015). Krotoski, W. A. et al. Demonstration of Hypnozoites in Sporozoite-Transmitted Plasmodium vivax Infection. Am. J. Trop. Med. Hyg. 31 , 1291–1293 (1982). Dembélé, L. et al. Persistence and activation of malaria hypnozoites in long-term primary hepatocyte cultures. Nat. Med. 2014 203 20 , 307–312 (2014). Taylor, A. R. et al. Resolving the cause of recurrent Plasmodium vivax malaria probabilistically. Nat. Commun. 2019 101 10 , 1–11 (2019). Kitchen, S. F. The Infection of Reticulocytes by Plasmodium Vivax 1. Am. J. Trop. Med. Hyg. s1 - 18 , 347–359 (1938). Clark, M. A. et al. Plasmodium vivax infection compromises reticulocyte stability. Nat. Commun. 12 , 1–11 (2021). Kitchen, S. F. & Boyd, M. F. On the Infectiousness of Patients Infected with Plasmodium Vivax and Plasmodium Falciparum 1. Am. J. Trop. Med. Hyg. s1 - 17 , 253–262 (1937). Bousema, T. & Drakeley, C. Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clinical Microbiology Reviews vol. 24 377–410 (2011). Gonçalves, L. A., Cravo, P. & Ferreira, M. U. Emerging Plasmodium vivax resistance to chloroquine in South America: An overview. Mem. Inst. Oswaldo Cruz 109 , 534–539 (2014). Wellems, T. E. & Plowe, C. V. Chloroquine‐Resistant Malaria. J. Infect. Dis. 184 , 770–776 (2001). Sá, J. M. et al. Plasmodium vivax chloroquine resistance links to pvcrt transcription in a genetic cross. Nat. Commun. 2019 101 10 , 1–10 (2019). World Health Organization. World Malaria Report 2015 - World Health Organization. https://www.who.int/publications/i/item/9789241565158 (2015). Ferreira, M. U. et al. Monitoring Plasmodium vivax resistance to antimalarials: Persisting challenges and future directions. Int. J. Parasitol. Drugs Drug Resist. 15 , 9–24 (2021). Bhatnagar, R. S. et al. Structure of N-myristoyltransferase with bound myristoylCoA and peptide substrate analogs. Nat. Struct. Biol. 5 , 1091–1097 (1998). Thinon, E., Morales-Sanfrutos, J., Mann, D. J. & Tate, E. W. N-Myristoyltransferase Inhibition Induces ER-Stress, Cell Cycle Arrest, and Apoptosis in Cancer Cells. ACS Chem. Biol. 11 , 2165–2176 (2016). Karki, R. G. & Kulkarni, V. M. A feature based pharmacophore for Candida albicans MyristoylCoA: protein N-myristoyltransferase inhibitors. Eur. J. Med. Chem. 36 , 147–163 (2001). Frearson, J. A. et al. N-myristoyltransferase inhibitors as new leads to treat sleeping sickness. Nature 464 , 728–732 (2010). Herrera, L. J. et al. Validation of N-myristoyltransferase as Potential Chemotherapeutic Target in Mammal-Dwelling Stages of Trypanosoma cruzi. PLoS Negl. Trop. Dis. 10 , e0004540 (2016). Olaleye, T. O. et al. Peptidomimetic inhibitors of N-myristoyltransferase from human malaria and leishmaniasis parasites. Org. Biomol. Chem. 12 , 8132–8137 (2014). Rackham, M. D. et al. Discovery of high affinity inhibitors of Leishmania donovani N-myristoyltransferase. Medchemcomm 6 , 1761–1766 (2015). Fenwick, M. K. et al. Identification of and Structural Insights into Hit Compounds Targeting N-Myristoyltransferase for Cryptosporidium Drug Development. ACS Infect. Dis. 9 , 1821–1833 (2023). Bell, A. S. et al. Selective inhibitors of protozoan protein N-myristoyltransferases as starting points for tropical disease medicinal chemistry programs. PLoS Negl. Trop. Dis. 6 , (2012). Tate, E. W., Bell, A. S., Rackham, M. D. & Wright, M. H. N-Myristoyltransferase as a potential drug target in malaria and leishmaniasis. Parasitology 141 , 37–49 (2014). Schlott, A. C., Holder, A. A. & Tate, E. W. N -Myristoylation as a Drug Target in Malaria: Exploring the Role of N -Myristoyltransferase Substrates in the Inhibitor Mode of Action. ACS Infectious Diseases vol. 4 449–457 (2018). Zhao, C. & Ma, S. Recent Advances in The Discovery of N-Myristoyltransferase Inhibitors. ChemMedChem 9 , 2425–2437 (2014). Wright, M. H. et al. Validation of N-myristoyltransferase as an antimalarial drug target using an integrated chemical biology approach. Nat. Chem. 6 , 112–121 (2014). Rodríguez-Hernández, D. et al. Identification of potent and selective N-myristoyltransferase inhibitors of Plasmodium vivax liver stage hypnozoites and schizonts. Nat. Commun. 14 , (2023). Katsuno, K. et al. Hit and lead criteria in drug discovery for infectious diseases of the developing world. Nat. Rev. Drug Discov. 2015 1411 14 , 751–758 (2015). Siqueira-Neto, J. L. et al. nature reviews drug discovery Antimalarial drug discovery: progress and approaches. Nat. Rev. Drug Discov. | 22 , 807–826 (2023). Yang, T. et al. MalDA, Accelerating Malaria Drug Discovery. Trends in Parasitology vol. 37 493–507 (2021). Rackham, M. D. et al. Discovery of Novel and Ligand-Efficient Inhibitors of Plasmodium falciparum and Plasmodium vivax N -Myristoyltransferase. J. Med. Chem. 56 , 371–375 (2013). Masubuchi, M. et al. Synthesis and biological activities of benzofuran antifungal agents targeting fungal N-myristoyltransferase. Bioorg. Med. Chem. 11 , 4463–4478 (2003). Brand, S. et al. Discovery of a novel class of orally active trypanocidal N-Myristoyltransferase inhibitors. J. Med. Chem. 55 , 140–152 (2012). Harupa, A. et al. Identification of Selective Inhibitors of Plasmodium N-Myristoyltransferase by High-Throughput Screening. J. Med. Chem. 63 , 591–600 (2020). Bilsland, E. et al. Yeast-based automated high-throughput screens to identify anti-parasitic lead compounds. Open Biol. 3 , (2013). Schlott, A. C. et al. Structure-Guided Identification of Resistance Breaking Antimalarial N‑Myristoyltransferase Inhibitors. Cell Chem. Biol. 26 , 991-1000.e7 (2019). Braga, R. C. & Andrade, C. H. Assessing the performance of 3D pharmacophore models in virtual screening: how good are they? Curr. Top. Med. Chem. 13 , 1127–1138 (2013). Neves, B. J. et al. Best Practices for Docking-Based Virtual Screening. in Molecular Docking for Computer-Aided Drug Design: Fundamentals, Techniques, Resources and Applications 75–98 (Academic Press, 2021). doi:10.1016/B978-0-12-822312-3.00001-1. Goncalves, V. et al. Discovery of plasmodium vivax N -myristoyltransferase inhibitors: Screening, synthesis, and structural characterization of their binding mode. J. Med. Chem. 55 , 3578–3582 (2012). Schousboe, M. L. et al. Multiple Origins of Mutations in the mdr1 Gene—A Putative Marker of Chloroquine Resistance in P. vivax. PLoS Negl. Trop. Dis. 9 , 1–17 (2015). Borges, S. et al. Genomewide scan reveals amplification of mdr1 as a common denominator of resistance to mefloquine, lumefantrine, and artemisinin in Plasmodium chabaudi malaria parasites. Antimicrob. Agents Chemother. 55 , 4858–4865 (2011). Klokouzas, A. et al. Plasmodium falciparum expresses a multidrug resistance-associated protein. Biochem. Biophys. Res. Commun. 321 , 197–201 (2004). Katzmann, D. J., Burnett, P. E., Golin, J., Mahé, Y. & Moye-Rowley, W. S. Transcriptional control of the yeast PDR5 gene by the PDR3 gene product. Mol. Cell. Biol. 14 , 4653–4661 (1994). Mohasin, M. et al. A Review on Synthesis and Biological Applications of Quinoline Derivative as Fused Aromatic Compounds. Polycycl. Aromat. Compd. 1–30 (2023) doi:10.1080/10406638.2023.2270118. Herraiz, T., Guillén, H., González-Peña, D. & Arán, V. J. Antimalarial Quinoline Drugs Inhibit β-Hematin and Increase Free Hemin Catalyzing Peroxidative Reactions and Inhibition of Cysteine Proteases. Sci. Rep. 9 , 1–16 (2019). Baragana, B. et al. Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy. J. Med. Chem. 59 , 9672–9685 (2016). McCarthy, J. S. et al. A Phase 1, Placebo-controlled, Randomized, Single Ascending Dose Study and a Volunteer Infection Study to Characterize the Safety, Pharmacokinetics, and Antimalarial Activity of the Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048 . Clin. Infect. Dis. 71 , e657–e664 (2020). Merck Healthcare. Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2). https://clinicaltrials.gov/study/NCT05974267 (2023). Merck Healthcare. Phase IIa Proof of Concept Study of M5717-Pyronaridine in Adults and Adolescents With Acute Uncomplicated Plasmodium Falciparum Malaria (CAPTURE 1). https://clinicaltrials.gov/study/NCT05689047 (2023). Skjærven, L., Yao, X.-Q., Scarabelli, G. & Grant, B. J. Integrating protein structural dynamics and evolutionary analysis with Bio3D. BMC Bioinforma. 2014 151 15 , 1–11 (2014). Grant, B. J., Skjærven, L. & Yao, X. Q. The Bio3D packages for structural bioinformatics. Protein Sci. 30 , 20–30 (2021). Yu, Z. et al. Design and synthesis of inhibitors of plasmodium falciparum N -myristoyltransferase, a promising target for antimalarial drug discovery. J. Med. Chem. 55 , 8879–8890 (2012). Velázquez-Libera, J. L., Durán-Verdugo, F., Valdés-Jiménez, A., Núñez-Vivanco, G. & Caballero, J. LigRMSD: a web server for automatic structure matching and RMSD calculations among identical and similar compounds in protein-ligand docking. Bioinformatics 36 , 2912–2914 (2020). Goncalves, V. et al. A fluorescence-based assay for N-myristoyltransferase activity. Anal. Biochem. 421 , 342–344 (2012). Goncalves, V. et al. Structure-guided optimization of quinoline inhibitors of Plasmodium N-myristoyltransferase. Medchemcomm 8 , 191–197 (2017). Fourches, D., Muratov, E. & Tropsha, A. Trust, but verify: On the importance of chemical structure curation in cheminformatics and QSAR modeling research. J. Chem. Inf. Model. 50 , 1189–1204 (2010). Fourches, D., Muratov, E. & Tropsha, A. Trust, but Verify II: A Practical Guide to Chemogenomics Data Curation. J. Chem. Inf. Model. 56 , 1243–1252 (2016). O’Boyle, N. M. et al. Open Babel: An open chemical toolbox. J. Cheminformatics 2011 31 3 , 1–14 (2011). Friedrich, N. O. et al. Benchmarking Commercial Conformer Ensemble Generators. J. Chem. Inf. Model. 57 , 2719–2728 (2017). Jakalian, A., Bush, B. L., Jack, D. B. & Bayly, C. I. Fast, Efficient Generation of High-Quality Atomic Charges. AM1-BCC Model: I. Method. J. Comput. Chem. 21 , 132–146 (2000). Jakalian, A., Jack, D. B. & Bayly, C. I. Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation. J. Comput. Chem. 23 , 1623–1641 (2002). v. 2.0.1.2 OpenEye Scientific Software Santa Fe, NM, H. eyesopen. co. QUACPAC. Hawkins, P. C. D., Skillman, A. G. & Nicholls, A. Comparison of shape-matching and docking as virtual screening tools. J. Med. Chem. 50 , 74–82 (2007). Neves, B. J. et al. Discovery of New Anti-Schistosomal Hits by Integration of QSAR-Based Virtual Screening and High Content Screening. J. Med. Chem. 59 , 7075–7088 (2016). Huang, Z. & Wong, C. F. Inexpensive Method for Selecting Receptor Structures for Virtual Screening. J. Chem. Inf. Model. 56 , 21–34 (2016). Pearlman, D. A. & Charifson, P. S. Improved scoring of ligand-protein interactions using OWFEG free energy grids. J. Med. Chem. 44 , 502–511 (2001). Halgren, T. A. et al. Glide: A New Approach for Rapid, Accurate Docking and Scoring. 2. Enrichment Factors in Database Screening. J. Med. Chem. 47 , 1750–1759 (2004). Mousnier, A. et al. Fragment-derived inhibitors of human N-myristoyltransferase block capsid assembly and replication of the common cold virus. Nat. Chem. 10 , 599–606 (2018). Madhavi Sastry, G., Adzhigirey, M., Day, T., Annabhimoju, R. & Sherman, W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J. Comput. Aided. Mol. Des. 27 , 221–234 (2013). Shelley, J. C. et al. Epik: A software program for pKa prediction and protonation state generation for drug-like molecules. J. Comput. Aided. Mol. Des. 21 , 681–691 (2007). Greenwood, J. R., Calkins, D., Sullivan, A. P. & Shelley, J. C. Towards the comprehensive, rapid, and accurate prediction of the favorable tautomeric states of drug-like molecules in aqueous solution. J. Comput. Aided. Mol. Des. 24 , 591–604 (2010). Jorgensen, W. L. & Tirado-Rives, J. The OPLS Potential Functions for Proteins. Energy Minimizations for Crystals of Cyclic Peptides and Crambin. Annu. Rev. Biophys. Bioeng 110 , 411 (1988). Shivakumar, D., Harder, E., Damm, W., Friesner, R. A. & Sherman, W. Improving the prediction of absolute solvation free energies using the next generation opls force field. J. Chem. Theory Comput. 8 , 2553–2558 (2012). Friesner, R. A. et al. Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy. J. Med. Chem. 47 , 1739–1749 (2004). Repasky, M. P. et al. Docking performance of the glide program as evaluated on the Astex and DUD datasets: A complete set of glide SP results and selected results for a new scoring function integrating WaterMap and glide. J. Comput. Aided. Mol. Des. 26 , 787–799 (2012). Berthold, M. R. et al. KNIME: The Konstanz information miner. in Studies in Classification, Data Analysis, and Knowledge Organization 319–326 (Springer, Berlin, Heidelberg, 2008). Li, J. et al. The VSGB 2.0 model: A next generation energy model for high resolution protein structure modeling. Proteins Struct. Funct. Bioinforma. 79 , 2794–2812 (2011). Borrelli, K. W., Cossins, B. & Guallar, V. Exploring Hierarchical Refinement Techniques for Induced Fit Docking with Protein and Ligand Flexibility. J Comput Chem 31 , 1224–1235 (2010). Cappel, D. et al. Relative Binding Free Energy Calculations Applied to Protein Homology Models. J. Chem. Inf. Model. 56 , 2388–2400 (2016). Neves, B. J. et al. Deep Learning-driven research for drug discovery: Tackling malaria. PLoS Comput. Biol. 16 , (2020). Sander, T., Freyss, J., Von Korff, M. & Rufener, C. DataWarrior: An open-source program for chemistry aware data visualization and analysis. J. Chem. Inf. Model. 55 , 460–473 (2015). Daina, A., Michielin, O. & Zoete, V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 7 , 1–13 (2017). Bowers, K. J. et al. Scalable Algorithms for Molecular Dynamics Simulations on Commodity Clusters. SC ’06 Proc. 2006 ACM/IEEE Conf. Supercomput. 43–43 (2007) doi:10.1109/SC.2006.54. Jorgensen, W. L. Transferable Intermolecular Potential Functions for Water, Alcohols, and Ethers. Application to Liquid Water. J. Am. Chem. Soc. 103 , 335–340 (1981). Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W. & Klein, M. L. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 79 , 926–935 (1983). Lu, C. et al. OPLS4: Improving force field accuracy on challenging regimes of chemical space. J. Chem. Theory Comput. 17 , 4291–4300 (2021). Martyna, G. J., Klein, M. L. & Tuckerman, M. Nosé-Hoover chains: The canonical ensemble via continuous dynamics. J. Chem. Phys. 97 , 2635–2643 (1992). Martyna, G. J., Tobias, D. J. & Klein, M. L. Constant pressure molecular dynamics algorithms. J. Chem. Phys. 101 , 4177–4189 (1994). Bilsland, E. et al. Functional expression of parasite drug targets and their human orthologs in yeast. PLoS Negl. Trop. Dis. 5 , (2011). Fernandez-Ricaud, L., Kourtchenko, O., Zackrisson, M., Warringer, J. & Blomberg, A. PRECOG: A tool for automated extraction and visualization of fitness components in microbial growth phenomics. BMC Bioinformatics 17 , 1–15 (2016). Scherr, C., Baumgartner, S., Spranger, J. & Simon, M. Effects of Potentised Substances on Growth Kinetics of Saccharomyces cerevisiae and Schizosaccharomyces pombe. Complement. Med. Res. 13 , 298–306 (2006). Trager, W. & Jensen, J. B. Human malaria parasites in continuous culture. Science 193 , 673–5 (1976). Smilkstein, M., Sriwilaijaroen, N., Kelly, J. X., Wilairat, P. & Riscoe, M. Simple and Inexpensive Fluorescence-Based Technique for High-Throughput Antimalarial Drug Screening. Antimicrob. Agents Chemother. 48 , 1803–1806 (2004). Leidenberger, M., Voigtländer, C., Simon, N. & Kappes, B. SYBR® green I-based fluorescence assay to assess cell viability of malaria parasites for routine use in compound screening. Methods Mol. Biol. 1601 , 97–110 (2017). Wang, C., Qin, X., Huang, B., He, F. & Zeng, C. Hemolysis of human erythrocytes induced by melamine-cyanurate complex. Biochem. Biophys. Res. Commun. 402 , 773–777 (2010). Kumar, P., Nagarajan, A. & Uchil, P. D. Analysis of Cell Viability by the MTT Assay. Cold Spring Harb. Protoc. 2018 , pdb.prot095505 (2018). Goncalves, V. et al. A fluorescence-based assay for N-myristoyltransferase activity. Anal. Biochem. 421 , 342–344 (2012). Tables Table 2 is available in the Supplementary Files section. Additional Declarations There is NO Competing Interest. Supplementary Files PvNMTVSSupplementraryInformationCommsChem.docx SupplementaryDatafile1.pdf Table2.docx Cite Share Download PDF Status: Under Review Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-3963523","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":273625427,"identity":"6f13694b-25d5-4ee5-8a7c-5d8567624f46","order_by":0,"name":"Carolina Andrade","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAAuklEQVRIie3PsQrCMBCA4TsCWbPGyVc46eIivkpKoI4KvkAnO3btYwhCcRQKTnHPIBIRimPdHQy6uDXdBPPDjR93BxCL/WqOAASgA8xDifJklDMaQvzQIZSI4nR1anUeJ1azO+4v/USaRUKK2kltNZ+iWfcTgoxLRQ3Wdnkk3KgAIto3me8qzQOJ/GxJt1IzF0SkbZn/pdGVuXFITQARZYauezazstCse+wDyHf+wmEAgHVDRSwWi/1HLzPVOU2Op/tGAAAAAElFTkSuQmCC","orcid":"https://orcid.org/0000-0003-0101-1492","institution":"Federal University of Goias","correspondingAuthor":true,"prefix":"","firstName":"Carolina","middleName":"","lastName":"Andrade","suffix":""},{"id":273625428,"identity":"6e2a80db-fbae-48a6-88a1-124aaf76ee8c","order_by":1,"name":"Bruna Katiele de Paula Sousa","email":"","orcid":"https://orcid.org/0000-0002-3204-5591","institution":"Universidade Federal de Goiás","correspondingAuthor":false,"prefix":"","firstName":"Bruna","middleName":"Katiele de Paula","lastName":"Sousa","suffix":""},{"id":273625429,"identity":"6bbe71e1-2885-4321-a100-699f0fc75438","order_by":2,"name":"Sunniva Sigurdardóttir","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Sunniva","middleName":"","lastName":"Sigurdardóttir","suffix":""},{"id":273625430,"identity":"6c1e1060-286c-4698-a428-5d15ed682cdc","order_by":3,"name":"Catarina Bourgard","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Catarina","middleName":"","lastName":"Bourgard","suffix":""},{"id":273625431,"identity":"1fc0adf1-b712-4511-871a-3c8dfe3edf71","order_by":4,"name":"Joyce Borba","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Joyce","middleName":"","lastName":"Borba","suffix":""},{"id":273625432,"identity":"d034aa87-3fba-40a5-9b1f-2a300f9040ac","order_by":5,"name":"Leandro Clementino","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Leandro","middleName":"","lastName":"Clementino","suffix":""},{"id":273625433,"identity":"e06f225c-ccbf-4133-9f2b-9b9909d71964","order_by":6,"name":"Luis Carlos Salazar-Alvarez","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Luis","middleName":"Carlos","lastName":"Salazar-Alvarez","suffix":""},{"id":273625434,"identity":"bdd4b19e-5dad-40f1-bbc6-97600aa6ee72","order_by":7,"name":"Sophia Groustra","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Sophia","middleName":"","lastName":"Groustra","suffix":""},{"id":273625435,"identity":"f32528b3-71f5-46db-bc83-48060e285b2f","order_by":8,"name":"Rachael Zigweid","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Rachael","middleName":"","lastName":"Zigweid","suffix":""},{"id":273625436,"identity":"5913c426-88d7-4aca-b97d-5ba035c866b9","order_by":9,"name":"Monique Khim","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Monique","middleName":"","lastName":"Khim","suffix":""},{"id":273625437,"identity":"90eddb06-fa11-4def-9f80-e710ddd19198","order_by":10,"name":"Bart Staker","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Bart","middleName":"","lastName":"Staker","suffix":""},{"id":273625438,"identity":"03648c5b-899c-4933-ae20-6b7bd89d8098","order_by":11,"name":"Fabio Costa","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Fabio","middleName":"","lastName":"Costa","suffix":""},{"id":273625439,"identity":"2454d84c-a8f6-4e88-8603-ce52a0d9adf1","order_by":12,"name":"Leif Eriksson","email":"","orcid":"https://orcid.org/0000-0001-5654-3109","institution":"University of Gothenburg","correspondingAuthor":false,"prefix":"","firstName":"Leif","middleName":"","lastName":"Eriksson","suffix":""},{"id":273625440,"identity":"efaa2b28-4d1d-400f-9d77-36bf1e62858a","order_by":13,"name":"Per Sunnerhagen","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Per","middleName":"","lastName":"Sunnerhagen","suffix":""}],"badges":[],"createdAt":"2024-02-17 08:35:23","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-3963523/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-3963523/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":51364427,"identity":"c9abd830-8446-4ecc-9bb3-72f495cae288","added_by":"auto","created_at":"2024-02-20 09:38:41","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":431175,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eOverview of the study’s rationale for the development of new inhibitors targeting PvNMT. \u003c/strong\u003eThe process encompasses initial data acquisition from the Protein Data Bank (PDB) and literature-derived inhibitors, followed by structural analysis, shape-based and docking model development, and validation. Subsequently, a virtual screening campaign is conducted to prioritize compounds for \u003cem\u003ein vitro\u003c/em\u003e validation, utilizing NMT yeast-based assays, malaria phenotypical and cytotoxicity assays, and NMT enzymatic assays. The most promising candidates undergo molecular dynamics simulations to analyse their binding modes.\u003c/p\u003e","description":"","filename":"image1.png","url":"https://assets-eu.researchsquare.com/files/rs-3963523/v1/9dda524d8c0958f45040f5bf.png"},{"id":51363367,"identity":"ab258611-21eb-490d-8551-c5204e258159","added_by":"auto","created_at":"2024-02-20 09:30:41","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":200851,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003ePrincipal Component Analysis \u003c/strong\u003e(\u003cstrong\u003ePCA) analysis depicting clustering of structural conformations of \u003c/strong\u003e\u003cem\u003e\u003cstrong\u003ePlasmodium\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003e NMT.\u003c/strong\u003e Panel \u003cstrong\u003ea\u003c/strong\u003e illustrates the comparison between PvNMT and HsNMT structures, revealing two distinct groups of conformations. Panel \u003cstrong\u003eb\u003c/strong\u003e showcases a heterogeneous separation among the PvNMT structures.\u003c/p\u003e","description":"","filename":"image2.png","url":"https://assets-eu.researchsquare.com/files/rs-3963523/v1/946c0fcbd4b25798a3d4002c.png"},{"id":51363369,"identity":"57e39ac1-d8a6-4379-b18a-a69bd79f7997","added_by":"auto","created_at":"2024-02-20 09:30:41","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":285789,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003ePvNMT shape-based models. \u003c/strong\u003eChemical structures, corresponding PDB-IDs and activities against \u003cem\u003ePlasmodium\u003c/em\u003eNMT, utilized for the development and validation of the PvNMT shape-based models.\u003c/p\u003e","description":"","filename":"image3.png","url":"https://assets-eu.researchsquare.com/files/rs-3963523/v1/8aef4a023e6cbb1b60f2854e.png"},{"id":51363375,"identity":"5804c0a3-a347-45e2-a069-982b52c065ff","added_by":"auto","created_at":"2024-02-20 09:30:41","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":256658,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eMolecular filters applied during virtual screening against PvNMT. \u003c/strong\u003eThe\u003cstrong\u003e \u003c/strong\u003eprocess the validated PvNMT shape-based model was employed as first filter, followed by the implementation of a selective docking protocol and the utilization of malaria QSAR models. Finally, clustering, visual inspections and assessment of ADMET properties were conducted.\u003c/p\u003e","description":"","filename":"image4.png","url":"https://assets-eu.researchsquare.com/files/rs-3963523/v1/b3b6aad8bb6520cd7c97e530.png"},{"id":51363372,"identity":"6cd0a436-6799-41a7-9f0e-ad0182b790b3","added_by":"auto","created_at":"2024-02-20 09:30:41","extension":"png","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":94596,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eGrowth ratio of compounds exhibiting an inhibitor phenotype against NMT yeast-based platform.\u003c/strong\u003e Seven compounds demonstrated the inhibitor phenotype compared to the growth control.\u003c/p\u003e","description":"","filename":"image5.png","url":"https://assets-eu.researchsquare.com/files/rs-3963523/v1/8c28ebbaebb8abdbb976147e.png"},{"id":51364428,"identity":"7aa8489f-309a-4861-b140-210857d863c7","added_by":"auto","created_at":"2024-02-20 09:38:41","extension":"png","order_by":6,"title":"Figure 6","display":"","copyAsset":false,"role":"figure","size":116862,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eTwo-concentration activity assay of 23 potential hit compounds.\u003c/strong\u003e Control 02 is the known NMT inhibitor DDD85646.\u003c/p\u003e","description":"","filename":"image6.png","url":"https://assets-eu.researchsquare.com/files/rs-3963523/v1/ba9cb4cac4adefb354dd8c6e.png"},{"id":51363376,"identity":"542c3ec4-60f2-472f-b57e-1bd0e7a85523","added_by":"auto","created_at":"2024-02-20 09:30:41","extension":"png","order_by":7,"title":"Figure 7","display":"","copyAsset":false,"role":"figure","size":377390,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eDynamic interactions between PvNMT and LabMol-394 during a 300 ns MD simulation. (A)\u003c/strong\u003e The root mean square deviation (RMSD) of the α carbon atoms of the protein in wine, and blue represents the ligand’s RMSD values. (B) Protein-ligand contacts, presenting the normalized fraction of interactions sustained during the simulation. (C)\u003cstrong\u003e \u003c/strong\u003eA representative MD pose is shown, highlighting interactions persisting for at least 50% of the simulation duration. LabMol-394 is shown in green, while interacting residues of PvNMT are highlighted residues. \u0026nbsp;𝜋-𝜋 stacking interactions are represented by black dashed dots, and 𝜋-cation interactions are represented by pink dashed lines. The key residue Leu410 is highlighted in light pink.\u003c/p\u003e","description":"","filename":"image7.png","url":"https://assets-eu.researchsquare.com/files/rs-3963523/v1/25c9aaef451abf63a158434e.png"},{"id":51364912,"identity":"79567a3c-f542-4cf1-b1b9-b0e4bcdb6970","added_by":"auto","created_at":"2024-02-20 09:46:43","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":2468853,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-3963523/v1/bc4939e8-dad9-4ece-a8b7-98676a418261.pdf"},{"id":51363370,"identity":"64cd65c3-18c6-4167-bead-765c569ea879","added_by":"auto","created_at":"2024-02-20 09:30:41","extension":"docx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":1239934,"visible":true,"origin":"","legend":"","description":"","filename":"PvNMTVSSupplementraryInformationCommsChem.docx","url":"https://assets-eu.researchsquare.com/files/rs-3963523/v1/39d9446ec0e3437d1f782ed4.docx"},{"id":51363374,"identity":"1cdbefdf-373b-4414-8d98-2f2d6eed585c","added_by":"auto","created_at":"2024-02-20 09:30:41","extension":"pdf","order_by":2,"title":"","display":"","copyAsset":false,"role":"supplement","size":1731533,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cbr\u003e\u003c/p\u003e","description":"","filename":"SupplementaryDatafile1.pdf","url":"https://assets-eu.researchsquare.com/files/rs-3963523/v1/5692d3f3ccf66eedbe1b8d64.pdf"},{"id":51363373,"identity":"89af99a8-6664-4f73-b3ee-89100c74314b","added_by":"auto","created_at":"2024-02-20 09:30:41","extension":"docx","order_by":3,"title":"","display":"","copyAsset":false,"role":"supplement","size":94563,"visible":true,"origin":"","legend":"","description":"","filename":"Table2.docx","url":"https://assets-eu.researchsquare.com/files/rs-3963523/v1/008dfebff0f6b808a826847e.docx"}],"financialInterests":"There is \u003cb\u003eNO\u003c/b\u003e Competing Interest.","formattedTitle":"Selective Bias Virtual Screening for Discovery of Promising Antimalarial Candidates targeting Plasmodium N-Myristoyltransferase","fulltext":[{"header":"Introduction","content":"\u003cp\u003eMalaria is a disease caused by protozoa of the \u003cem\u003ePlasmodium\u003c/em\u003e genus, specifically the species \u003cem\u003eP. falciparum and P. vivax\u003c/em\u003e\u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u003c/sup\u003e that cause the highest rates of mortality and morbidity, respectively. In 2022, global estimates surpassed 200\u0026nbsp;million cases, resulting in over 600 thousand deaths\u003csup\u003e\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e\u003c/sup\u003e. Vivax malaria, the most geographically widespread form of the disease, is predominantly found in tropical and subtropical regions. Cases caused by \u003cem\u003eP. vivax\u003c/em\u003e account for approximately 72% of all malaria episodes occurring outside the African continent\u003csup\u003e\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e\u003c/sup\u003e. Notably, around 73% of reported cases in the Americas are concentrated in Venezuela, Brazil and Colombia\u003csup\u003e\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e,\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003e \u003cem\u003eP. vivax\u003c/em\u003e is biologically distinct from \u003cem\u003eP. falciparum\u003c/em\u003e primarily due to the formation of hypnozoites, a latent stage that persists in the liver, posing a challenge for treatment due to the relapse episodes\u003csup\u003e\u003cspan additionalcitationids=\"CR6 CR7\" citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u003c/sup\u003e. Additionally, \u003cem\u003eP. vivax\u003c/em\u003e is characterized by its preference for reticulocyte infection\u003csup\u003e\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e,\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e\u003c/sup\u003e and the early production of sexual stages (gametocytes) observed in peripheral blood\u003csup\u003e\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e,\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e\u003c/sup\u003e. An additional concern is related to the growing resistance of \u003cem\u003eP. vivax\u003c/em\u003e to chloroquine\u003csup\u003e\u003cspan additionalcitationids=\"CR14\" citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u003c/sup\u003e. Despite being a frontline treatment for vivax malaria since 1946, current evidence shows the circulation of resistant strains in endemic areas across various continents, including the Americas\u003csup\u003e\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e\u003c/sup\u003e. Evaluating drug resistance in \u003cem\u003eP. vivax\u003c/em\u003e is particularly challenging due to the difficulties in \u003cem\u003ein vitro\u003c/em\u003e culturing of the parasite. Distinguishing between treatment resistance and late relapses identified in \u003cem\u003ein vivo\u003c/em\u003e assessments adds complexity to the analysis\u003csup\u003e\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u003c/sup\u003e. Given these challenges, there is a pressing need to explore new therapeutic options for \u003cem\u003eP. vivax\u003c/em\u003e.\u003c/p\u003e \u003cp\u003eThe \u003cem\u003eN\u003c/em\u003e- myristoyltransferase protein (NMT) plays a crucial role in catalyzing the transfer of the fatty acid myristate (C14) from the myristoyl-CoA molecule to the \u003cem\u003eN\u003c/em\u003e-terminal glycine residue of numerous proteins\u003csup\u003e\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e\u003c/sup\u003e. In humans, this protein exhibits two isoforms, attracting attention in cancer research as important targets for cell survival\u003csup\u003e\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e\u003c/sup\u003e. In contrast, in various organisms, such as \u003cem\u003eCandida albicans\u003c/em\u003e\u003csup\u003e\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e\u003c/sup\u003e, \u003cem\u003eTrypanossoma spp.\u003c/em\u003e\u003csup\u003e\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e,\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e\u003c/sup\u003e, \u003cem\u003eLeishmania donovani\u003c/em\u003e\u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e,\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e\u003c/sup\u003e, \u003cem\u003eCryptosporidium parvum\u003c/em\u003e\u003csup\u003e\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e\u003c/sup\u003e, and \u003cem\u003ePlasmodium spp.\u003c/em\u003e\u003csup\u003e\u003cspan additionalcitationids=\"CR27\" citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e\u003c/sup\u003e, which express a single isoform of the protein, NMT stands out as a promising drug target. This has prompted extensive research to discover new therapeutic agents for diseases associated with these organisms\u003csup\u003e\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e\u003c/sup\u003e. Studies revealed that many \u003cem\u003ePlasmodium\u003c/em\u003e proteins need this post-translational modification during various life stages of the parasite\u003csup\u003e\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e\u003c/sup\u003e, which is important for drug development of inhibitors. While inhibitors for \u003cem\u003ePlasmodium\u003c/em\u003e NMT are currently described, achieving parasite selectivity remains a challenge. Efforts are underway to enhance the selectivity of these inhibitors for more effective targeting of the parasite. Structural studies revealed that the \u003cem\u003ePlasmodium\u003c/em\u003e NMT enzyme is capable of forming an alternate conformation in the peptide binding pocket which preferentially binds some inhibitors compared to the human enzymes thus providing a rational hypothesis for how to achieve selectivity\u003csup\u003e\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e\u003c/sup\u003e. Structural studies of these selective hits support the identification of a distinct conformation of the \u003cem\u003ePlasmodium\u003c/em\u003e enzyme which binds compounds preferentially compared to the human NMTs\u003csup\u003e\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e,\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e\u003c/sup\u003e. In this study (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e), we employed structural analysis and virtual screening of millions of commercially available compounds using validated, robust, and predictive computational models as filters. This process enabled us to select 23 candidates for subsequent \u003cem\u003ein vitro\u003c/em\u003e evaluation. Our approach involved experimental testing within a developed NMT yeast system, followed by \u003cem\u003eP. falciparum in vitro\u003c/em\u003e phenotypic and cytotoxicity assays. Subsequently, the selected candidates underwent evaluation against NMT enzyme. To deepen our understanding, molecular dynamics simulations were conducted to elucidate the binding mode of the most promising candidates. Through this synergistic integration of computational models and experimental evaluation, we successfully identified LabMol-394 as a promising compound targeting the translational process of malaria parasites.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e"},{"header":"Results","content":"\u003cp\u003e \u003cem\u003eIn silico\u003c/em\u003e studies\u003c/p\u003e \u003cp\u003e \u003cb\u003eFive high-affinity representative binding sites identified through structural analysis.\u003c/b\u003e \u003c/p\u003e \u003cp\u003eUtilizing data from PDB (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.rcsb.org/\u003c/span\u003e\u003cspan address=\"https://www.rcsb.org/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003cspan type=\"Underline\" class=\"Underline\" name=\"Emphasis\"\u003e)\u003c/span\u003e, we collected 59 structures of NMT from \u003cem\u003eH. sapiens\u003c/em\u003e (isoforms 1 and 2) and \u003cem\u003eP. vivax\u003c/em\u003e. To conduct structural analysis using the Bio3D R package, we filtered the crystals based on the presence of a ligand, absence of mutations, and high resolution (\u0026le;\u0026thinsp;2 \u0026Aring;), resulting in a total of 30 structures (10 for \u003cem\u003eH. sapiens\u003c/em\u003e and 20 for \u003cem\u003eP. vivax\u003c/em\u003e). This comprehensive analysis involved aligning these structures followed by principal component analysis (PCA) to categorize similar conformations into clusters. Notably, our findings revealed distinct binding modes between \u003cem\u003ePlasmodium\u003c/em\u003e compared to \u003cem\u003eH. sapiens\u003c/em\u003e (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003ea). Building upon this insight, we focused on \u003cem\u003ePlasmodium\u003c/em\u003e structures, identifying five clusters showcasing variations in conformation and ligand binding (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eb). Subsequently, we selected the most representative structures based on inhibition (Ki or IC\u003csub\u003e50\u003c/sub\u003e) from PDB IDs: 2YND, 2YNE, 4CAF, 4UFX and 6MB1. These structures served as the foundation for developing and validating both shape-based models and docking protocols.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eValidation of PvNMT Shape-based models\u003c/h2\u003e \u003cp\u003eThe selected representative structures were employed to construct and validate shape-based models, as depicted in Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003e. Notably, the application of RefTverskyCombo score yielded area under the curve (AUC) values ranging from 0.69 to 0.86 across all models. Particularly, the model generated using query PDB ID 2YNE demonstrated the highest performance, achieving an AUC of 0.86, along with an Enrichment Factor (EF) of 7.76 and BEDROC (Boltzmann-Enhanced Discrimination of ROC) score of 0.75 at the top 10%. These findings, summarized in Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e, provide compelling evidence for the efficacy of the best-performing shape-based model, which exhibits satisfactory metrics and hence serves as a reliable filter in the virtual screening process.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eValidation of shape-based models employing different queries and \u003cem\u003eRefTverskyCombo\u003c/em\u003e score.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"8\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c8\" colnum=\"8\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eQueries\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eAUC\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003eTOP 1%\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003eTOP 5%\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c8\" namest=\"c7\"\u003e \u003cp\u003eTOP 10%\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eEF\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eBEDROC\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eEF\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003eBEDROC\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c7\"\u003e \u003cp\u003eEF\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c8\"\u003e \u003cp\u003eBEDROC\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e2YND\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e0.77\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e5.66\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.21\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e4.48\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e0.23\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e3.28\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.29\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cb\u003e2YNE*\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e\u003cb\u003e0.86\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e\u003cb\u003e37.00\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e\u003cb\u003e0.88\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e\u003cb\u003e17.63\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e\u003cb\u003e0.74\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e\u003cb\u003e7.76\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e\u003cb\u003e0.75\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e4CAF\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e0.73\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e1.49\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.08\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e3.58\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e0.13\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e3.13\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.21\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e4UFX\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e0.84\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e23.88\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.65\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e14.93\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e0.68\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e7.61\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.72\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e6MB1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e0.69\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e7.46\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.20\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e3.88\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e0.19\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e2.09\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e0.22\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003eAUC: Area under the ROC curve; EF: Enrichment Factor; BEDROC: Boltzmann-Enhanced Discrimination of ROC. *Selected model.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003eSelective bias docking and post -processing with MMGBSA correlates with PvNMT activity\u003c/h2\u003e \u003cp\u003eTo ensure the reliability of the docking program, validation was conducted using a prepared dataset of inhibitors and decoys along with the crystal structure of PvNMT PDB ID 2YNE, derived from the best-performing shape-based model. The results obtained from the top 10% of the ranked list yielded metrics including an AUC of 0.863, EF of 6.62 and a BEDROC of 0.65, all of which were considered satisfactory, validating the utilization of the Glide program for docking purposes. Subsequent redocking procedure involving the ligand at PDB ID 2YNE (2-(3-piperidin-4-yloxy-1-benzothiophen-2-yl)-5-[(1,3,5-trimethylpyrazol-4-yl) methyl]-1,3,4-oxadiazole), and its interaction with \u003cem\u003ePlasmodium\u003c/em\u003e and human isoforms (I and II), revealed several key binding interactions. In \u003cem\u003eP. vivax\u003c/em\u003e, the inhibitor primarily engages in π-stacking interactions with Phe105 and Tyr211, while also forming a hydrogen bond mediated by a water molecule with Ser319, and establishing a donor-salt bridge interaction between the piperidine ring and Leu410. This interaction yielded a docking score of -12.66 Kcal/mol and a predicted MMGBSA-ΔG of -99.37 Kcal/mol. Similarly, when interacting with HsNMT-1, the ligand engages in π-stacking interactions with tyrosines 296 and 420, forms a hydrogen bond with Ser405 (equivalent to Ser319 in \u003cem\u003eP. vivax\u003c/em\u003e), and establishes a salt bridge interaction with Gln496 (analogous to Leu410 in \u003cem\u003eP. vivax\u003c/em\u003e). This interaction resulted in a docking score of -10.81 Kcal/mol and a significant predicted MMGBSA-ΔG difference of -28.60 Kcal/mol. Conversely, when interacting with HsNMT-2, the docking results suggested predominantly hydrophobic interactions at the peptide binding site, resulting in a docking score of -3.63 Kcal/mol and an MMGBSA-ΔG of -27.42 Kcal/mol. These findings are consistent with the IC\u003csub\u003e50\u003c/sub\u003e for this ligand against human isoform 1 (60\u0026thinsp;\u0026plusmn;\u0026thinsp;3 nM), demonstrating potential selectivity against \u003cem\u003ePlasmodium\u003c/em\u003e (see Supplementary file, Fig. \u003cspan refid=\"MOESM1\" class=\"InternalRef\"\u003eS1\u003c/span\u003e).\u003c/p\u003e \u003cp\u003eFurthermore, we evaluated the correlation between pK\u003csub\u003ei\u003c/sub\u003e values and the predicted docking scores and MMGBSA values by calculating the correlation coefficient. Visual inspection of the data (see Supplementary file, Fig. \u003cspan refid=\"MOESM2\" class=\"InternalRef\"\u003eS2\u003c/span\u003e) reveals that the most potent compounds exhibit docking score and MMGBSA values lower than \u0026minus;\u0026thinsp;11 Kcal/mol and \u0026minus;\u0026thinsp;80 Kcal/mol, respectively. Therefore, based on the docking metrics, redocking results and MMGBSA post -processing values obtained, we concluded that the program effectively predicts values closely aligned with the activity of the most potent compounds in the PvNMT dataset.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003eVirtual Screening prioritizes 23 potential hits\u003c/h2\u003e \u003cp\u003eWith the models duly validated, the virtual screening was conducted applying the following filters (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003e):\u003c/p\u003e \u003cp\u003e \u003col\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003eUtilization of the best molecular shape-based model for PvNMT, where the top 10% (131,982 compounds) of the list progressed to filter 2 for subsequent docking and selective rescoring between \u003cem\u003eP. vivax\u003c/em\u003e and human isoforms.\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003eExamination of the top 10% of the list based on the MMGBSA-ΔG score (\u0026le; -70 kcal/mol). Compounds demonstrating a difference of \u0026le; -50 kcal/mol between HsNMT isoforms were singled out, resulting in the selection of 290 compounds.\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003eApplication of \u003cem\u003eP. falciparum\u003c/em\u003e 3D7 (mandatory) and W2 classificatory QSAR models to predict the activity of compounds selected in the previous step (80 compounds), given the importance of the target in asexual blood stages.\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003eImplementation of cluster analysis to identify representative chemotypes. Additionally, analysis of MMGBSA poses and evaluation of predicted ADMET characteristics were conducted. This comprehensive approach led to the final selection of 23 compounds (see Supplementary file, Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e).\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003c/ol\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003eExperimental evaluation\u003c/h2\u003e \u003cdiv id=\"Sec7\" class=\"Section3\"\u003e \u003ch2\u003eNMT yeast-based system for identification of potential inhibitors\u003c/h2\u003e \u003cp\u003eWe used a modified yeast strains system expressing the NMT targets of both \u003cem\u003eH. sapiens\u003c/em\u003e and \u003cem\u003eP. vivax\u003c/em\u003e that allows a fast and cost-effective identification of potential selective inhibitors and cytotoxic compounds. Cells were cultivated and subjected to tests at 100 \u0026micro;M in triplicate for each strain (yPvNMT, yHsNMT1 and ScNMT). Optical density (OD) was measured over a 72-hour period. In this assay, compound inhibition is determined by the reduction in growth rate compared to the control (180 \u0026micro;L of cells and 20 \u0026micro;L of YPD medium) in the presence of compound. As a result, seven compounds (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003e) presented an inhibition phenotype, with some demonstrating a degree of selectivity against the strain expressing \u003cem\u003eP. vivax\u003c/em\u003e NMT strain, as evidenced by a reduction in growth ratio (yield) compared to the human strain. Notably, LabMol-394 exhibited a vivax phenotype, indicating potential selectivity towards the parasite isoform.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003eFour compounds exhibited antimalarial activity\u003c/h2\u003e \u003cp\u003eTo evaluate the antimalarial activity of the compounds, we conducted tests against chloroquine-sensitive \u003cem\u003ePf\u003c/em\u003e3D7 and drug-resistant \u003cem\u003ePf\u003c/em\u003eDd2 and \u003cem\u003ePf\u003c/em\u003eSB1A6 strains, using a concentration of 5 \u0026micro;M, as detailed in Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e. Initially, we determined the percentage of parasite growth inhibition and subsequently generated dose-response (EC\u003csub\u003e50\u003c/sub\u003e) curves. Four compounds, LabMol-392, LabMol-393, LabMol-394, and LabMol-395, exhibited inhibition exceeding 80% against 3D7 strain parasites (see Supplementary file, Fig. S3 and S4), with EC\u003csub\u003e50\u003c/sub\u003e values ranging from 0.098 to 1.10 \u0026micro;M. Notably, all compounds tested exhibited low cytotoxicity, as evidenced by the selective index (the ratio of selectivity to the parasite over mammalian cells) higher than 10 (except for LabMol 393), aligning with guidelines for malaria drug development \u003csup\u003e\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e\u003c/sup\u003e. Furthermore, hemolysis tests were conducted at a maximum concentration of 20 \u0026micro;M indicated no hemolytic activity for any of the compounds tested (Supplementary file, Fig. S5).\u003c/p\u003e \u003cp\u003eThe most promising compound identified in the phenotypic screening is LabMol 395, demonstrating potent antimalarial activity below 0.17 \u0026micro;M against all three \u003cem\u003eP. falciparum\u003c/em\u003e strains tested herein. Moreover, it exhibits remarkable selectivity for the parasite over mammalian cells (SI\u0026thinsp;\u0026gt;\u0026thinsp;10), indicating significant potential for advancement in pre-clinical studies.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec9\" class=\"Section2\"\u003e \u003ch2\u003eNMT enzymatic assays revealed potential inhibitors\u003c/h2\u003e \u003cp\u003eWe conducted a two-point NMT inhibition assay of the top 23 potential inhibitors. Activity percentages were determined at 2 \u0026micro;M and 20 \u0026micro;M to identify a potential activity of compounds. Unfortunately, IC\u003csub\u003e50\u003c/sub\u003e calculations were not feasible due to compound solubility limitations. Nevertheless, the two-point enzymatic screen identified four promising compounds \u0026ndash; LabMol-391, LabMol-392, LabMol-393 and LabMol-394 \u0026ndash; which exhibited a minimum of 52% decrease in enzyme activity at a concentration of 20 \u0026micro;M against PvNMT (See Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003e). Regrettably, dose-response curves for the identified hits were hindered by compound precipitation at concentrations exceeding 40 \u0026micro;M. Subsequently, all compounds showing decreased activity were also tested against the human enzyme (HsNMT) in dose response studies ranging from 40 to 0.160 \u0026micro;M. Importantly, none of the compounds demonstrated inhibition of the human orthologue (HsNMT\u0026thinsp;\u0026gt;\u0026thinsp;40 \u0026micro;M, see Supplementary file, figures S6 and S7). These findings highlight four hit compounds that selectively inhibit PvNMT over HsNMT, thereby validating the efficacy of our computational selectivity approach.\u003c/p\u003e \u003cdiv id=\"Sec10\" class=\"Section2\"\u003e \u003ch2\u003eMolecular dynamics simulations to analyze the binding mode of LabMol-394\u003c/h2\u003e \u003cp\u003eMolecular dynamics simulations of 300 nanoseconds were conducted to evaluate the stability and binding dynamics of LabMol-394 with PvNMT. During this simulation, several significant interactions were observed. Although LabMol-394 (Fig.\u0026nbsp;\u003cspan refid=\"Fig7\" class=\"InternalRef\"\u003e7\u003c/span\u003e) does not directly engage with a critical residue, Leu410, it consistently maintains π-stacking interactions with residues Tyr211 and Phe105, occurring approximately 51% and 63% of the time, respectively. Intriguingly, a persistent hydrogen bond with Ser387 and the hydroxyl group was observed for approximately 34% of the simulation duration, while a π-cation interaction with Tyr211 and nitrogen of the pyridine ring was maintained for approximately 51% of the time.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e"},{"header":"Discussion","content":"\u003cp\u003eThe process of discovering compounds with biological activity is a significant challenge, demanding the application of robust and predictive methodologies to ensure reliable outcomes. Bioinformatics and cheminformatics analyses serve as foundational tools in the search for novel antimalarial agents. Their effectiveness is evident through validation and research efforts led by esteemed organizations such as MalDA, MMV, the Bill and Melinda Gates Foundation, and the pharmaceutical industry\u003csup\u003e\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eA crucial aspect of antimalarial drug discovery involves the identification of novel targets essential to the parasite\u0026rsquo;s life cycle and conserved among various \u003cem\u003ePlasmodium\u003c/em\u003e species. This strategy aims to encompass species previously overlooked as harmful to humans\u003csup\u003e\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e\u003c/sup\u003e. Consequently, the integration of computational strategies plays a crucial role in the discovery process, enabling the exploration of innovative mechanisms of action for potential new antimalarials.\u003c/p\u003e \u003cp\u003eThe NMT enzyme was validated as a target for antimalarial drugs in 2014\u003csup\u003e30\u003c/sup\u003e with many inhibitors initially repurposed from other organisms\u003csup\u003e\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e,\u003cspan additionalcitationids=\"CR36\" citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e\u003c/sup\u003e and through High Throughput Screening (HTS) campaigns\u003csup\u003e\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e,\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e\u003c/sup\u003e. The latest NMT inhibitors, highlighted by Rodr\u0026iacute;guez-Hern\u0026aacute;ndez and colleagues, particularly compounds 12b and 30a from the series of hybrids of DDD85646\u003csup\u003e30\u003c/sup\u003e and IMP-1002\u003csup\u003e40\u003c/sup\u003e PvNMT inhibitors studies, demonstrated significant potency \u003cem\u003ein vitro\u003c/em\u003e against PvNMT, with IC\u003csub\u003e50\u003c/sub\u003e of 0.0368 \u0026micro;M and 0.089 \u0026micro;M, respectively. However, their efficacy against hypnozoites and schizonts was observed to be in the low micromolar range\u003csup\u003e\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eIn our study, we initially conducted an analysis of structural conformations within a collection of crystal structures containing the new PvNMT inhibitor. This analysis allowed us to discern the various binding modes employed by the inhibitors. In parallel, a gathered set of compounds from the literature that had been tested against PvNMT, rigorously validating our shape-based and docking computational models, in accordance with established good practices\u003csup\u003e\u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e,\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e\u003c/sup\u003e. Subsequently, a virtual screening campaign was conducted. Our approach involved utilizing a predicted ΔG difference between \u003cem\u003ePlasmodium\u003c/em\u003e and human proteins as a filter to reevaluate the docking scores. This strategy enabled us to prioritize compounds that showed potential selectivity for the parasite. As a result, we identified and prioritized 23 compounds with promising characteristics for further investigation.\u003c/p\u003e \u003cp\u003eDuring the experimental validation phase, seven compounds exhibited a phenotypic effect against the modified yeast NMT strains. Next, the compounds were assessed for their efficacy against \u003cem\u003eP. falciparum\u003c/em\u003e strains, considering its significant identity (\u0026gt;\u0026thinsp;80%) of NMT between the species\u003csup\u003e\u003cspan citationid=\"CR43\" class=\"CitationRef\"\u003e43\u003c/span\u003e\u003c/sup\u003e. Notably, in \u003cem\u003eP. falciparum\u003c/em\u003e strains assays, four of these compounds demonstrated significant activity against three parasite strains, all at a single concentration of 5 \u0026micro;M, without any indications of cross-resistance and no signs of cytotoxicity (\u0026lt;\u0026thinsp;50 \u0026micro;M) or hemolysis, which are indicative of a favorable chemical safety profile. It's important to consider that the observed micromolar activity against the parasites may be influenced by the compounds' permeability to erythrocytic cells. Moreover, various efflux pumps, such as \u003cem\u003emdr1\u003c/em\u003e and \u003cem\u003emrp1\u003c/em\u003e in \u003cem\u003ePlasmodium\u003c/em\u003e, known for their role in resistance mechanisms\u003csup\u003e\u003cspan additionalcitationids=\"CR45\" citationid=\"CR44\" class=\"CitationRef\"\u003e44\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e\u003c/sup\u003e, could affect the activity of these compounds. In yeast cells, the primary efflux pump for drugs, the gene \u003cem\u003ePDR5\u003c/em\u003e, was deleted in the strains we used\u003csup\u003e\u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e\u003c/sup\u003e. This deletion leads to an increase in the concentration of compounds inside the cells, potentially explaining the divergent results observed for some compounds. One standout compound from these assays, LabMol-395, displayed an antimalarial efficacy below 0.17 \u0026micro;M against \u003cem\u003eP. falciparum\u003c/em\u003e strains examined. However, this particular compound did not exhibit a yeast phenotype against NMT, indicating that its antimalarial activity likely involves a different target.\u003c/p\u003e \u003cp\u003eOn enzymatic NMT assay, LabMol-394 exhibited modest activity, resulting in a 52% decrease in the activity of PvNMT at a concentration of 20 \u0026micro;M, displaying selectivity towards vivax over the human isoform. Molecular dynamics simulations revealed that LabMol-394 demonstrated interactions comparable to PvNMT inhibitors, including those used in the shape-based modeling. However, it lacked interaction with Ser319, previously suggested as a crucial residue in the proposed mechanism of NMT inhibition\u003csup\u003e\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e\u003c/sup\u003e. Throughout our simulations, LabMol-394 did not engage with a crucial residue, Leu410. However, it sustained significant π-stacking interactions with Tyr211 and Phe105 residues, while also forming a hydrogen bond with Ser387. Although Ser387 is not currently associated with inhibition in the literature, we hypothesize it as a potential mechanism.\u003c/p\u003e \u003cp\u003eChemically, LabMol-394 features a quinoline scaffold extensively documented for its diverse biological activities\u003csup\u003e\u003cspan citationid=\"CR48\" class=\"CitationRef\"\u003e48\u003c/span\u003e\u003c/sup\u003e. This scaffold is particularly renowned for its well-established antimalarial effects, primarily attributed to its inhibition of β-hematin and the formation of an irreversible complex with the heme group\u003csup\u003e\u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e49\u003c/span\u003e\u003c/sup\u003e. These actions disrupt the development of the parasite in both liver and red blood cells. Notably, recent reports unveiled a novel quinoline inhibitor targeting the translation elongation factor 2 (PfEF2), demonstrating multistage antimalarial properties and currently progressing through clinical stages\u003csup\u003e\u003cspan additionalcitationids=\"CR51 CR52\" citationid=\"CR50\" class=\"CitationRef\"\u003e50\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR53\" class=\"CitationRef\"\u003e53\u003c/span\u003e\u003c/sup\u003e. This discovery underscores the significance of heterocycles as crucial sources of chemical activities and introduces new mechanisms of inhibition aimed at pivotal targets in the \u003cem\u003ePlasmodium\u003c/em\u003e life cycle.\u003c/p\u003e \u003cp\u003eThe prioritized candidates in this study were experimentally validated and the results demonstrated a correlation between antimalarial activity and the absence of cytotoxicity. LabMol-395 emerged as promising candidate for target identification, due to its favorable antimalarial profile. Furthermore, enzymatic assays revealed LabMol-394 as the most promising PvNMT inhibitor, exhibiting selectivity against the parasite. Remarkably, there was a good correlation between the results obtained from the yeast system and enzymatic assays in NMT. This study makes a significant contribution to the exploration of the quinazoline scaffold, showcasing activity against \u003cem\u003ePlasmodium vivax\u003c/em\u003e NMT and offering prospects for further optimization and development.\u003c/p\u003e \u003c/div\u003e"},{"header":"Methods","content":"\u003cdiv id=\"Sec12\" class=\"Section2\"\u003e \u003cdiv id=\"Sec13\" class=\"Section3\"\u003e \u003ch2\u003eComputational\u003c/h2\u003e \u003cdiv id=\"Sec14\" class=\"Section4\"\u003e \u003ch2\u003eStructural analysis\u003c/h2\u003e \u003cp\u003eFor structural analysis, we utilized the Bio3D R package\u003csup\u003e\u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e54\u003c/span\u003e,\u003cspan citationid=\"CR55\" class=\"CitationRef\"\u003e55\u003c/span\u003e\u003c/sup\u003e, focusing on crystals with assigned ligand, no mutations and showed high resolution (\u0026le;\u0026thinsp;2 \u0026Aring;). This analysis comprised the alignment of these structures and then principal component analysis (PCA) of the conformations was performed.\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv id=\"Sec15\" class=\"Section2\"\u003e \u003ch2\u003eData collection and preparation\u003c/h2\u003e \u003cp\u003eTo distinguish active compounds from inactive ones, we constructed and validated shape-based models. Initially, compounds tested against the enzymes of both \u003cem\u003eP. falciparum\u003c/em\u003e and \u003cem\u003eP. vivax\u003c/em\u003e were collected from the literature \u003csup\u003e\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e,\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e,\u003cspan additionalcitationids=\"CR57 CR58\" citationid=\"CR56\" class=\"CitationRef\"\u003e56\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR59\" class=\"CitationRef\"\u003e59\u003c/span\u003e\u003c/sup\u003e. Subsequently, employing the protocol outlined by Fourches and colleagues\u003csup\u003e\u003cspan citationid=\"CR60\" class=\"CitationRef\"\u003e60\u003c/span\u003e,\u003cspan citationid=\"CR61\" class=\"CitationRef\"\u003e61\u003c/span\u003e\u003c/sup\u003e, we processed an initial set of 152 compounds. Briefly, the hydrogens were explicitly included while excluding counter ions, inorganic salts, polymers, mixtures, and organometallic compounds. We set a threshold for inhibitor activity considering compounds with Ki or IC\u003csub\u003e50\u003c/sub\u003e values\u0026thinsp;\u0026le;\u0026thinsp;1 \u0026micro;M as active and those with values\u0026thinsp;\u0026ge;\u0026thinsp;1 \u0026micro;M, as inactives. Additionally, specific chemotypes, such as aromatic and nitro groups, were standardized and duplicates were analyzed following the criteria: (i) entries with identical reported outcomes were consolidated, keeping only one, while the redundant entry was eliminated, and (ii) if duplicates exhibited inconsistent biological activity, both entries were removed from the dataset. Subsequently, the final dataset includes 137 unique compounds, comprising 67 inhibitors and 70 non-inhibitors. To augment the chemical diversity of the dataset, we generated 36 decoys for each inhibitor. The dataset, including actives, inactives and decoys, underwent appropriated hydrogen protonation state on neutral pH (7.4) using the Open Babel program\u003csup\u003e\u003cspan citationid=\"CR62\" class=\"CitationRef\"\u003e62\u003c/span\u003e\u003c/sup\u003e. Subsequently, for each molecule, 200 conformers were generated using the OMEGA\u003csup\u003e\u003cspan citationid=\"CR63\" class=\"CitationRef\"\u003e63\u003c/span\u003e\u003c/sup\u003e program, and AM1BCC charges\u003csup\u003e\u003cspan citationid=\"CR64\" class=\"CitationRef\"\u003e64\u003c/span\u003e,\u003cspan citationid=\"CR65\" class=\"CitationRef\"\u003e65\u003c/span\u003e\u003c/sup\u003e were estimated using the QUACPAC software\u003csup\u003e\u003cspan citationid=\"CR66\" class=\"CitationRef\"\u003e66\u003c/span\u003e\u003c/sup\u003e. Validated shape-based models were then built using the ligand conformations extracted from the Protein Data Bank (PDB) and employed as queries at the ROCS v. 3.4.2.1 program\u003csup\u003e\u003cspan citationid=\"CR67\" class=\"CitationRef\"\u003e67\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec16\" class=\"Section2\"\u003e \u003ch2\u003eShape-based model development and validation\u003c/h2\u003e \u003cp\u003eTo assess the predictive performance of the shape-based models, the following metrics were analyzed: Receiver Operating Characteristic (ROC) curve, which provides a graphical representation of the true positive rate (sensitivity) against the false positive rate (1-specificity); Area Under the ROC Curve (AUC), which quantifies the probability of an inhibitor being ranked higher than an inactive compound when compared to a random selection by the \u003cem\u003equery\u003c/em\u003e\u003csup\u003e\u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e,\u003cspan citationid=\"CR68\" class=\"CitationRef\"\u003e68\u003c/span\u003e\u003c/sup\u003e; Boltzmann-Enhanced Discrimination of ROC (BEDROC), which uses an exponential decay function to assign weights to actives that ranked higher in the list\u003csup\u003e\u003cspan citationid=\"CR69\" class=\"CitationRef\"\u003e69\u003c/span\u003e\u003c/sup\u003e; Enrichment Factor (EF), that evaluates the fraction of actives found at the Top \u003cem\u003en\u003c/em\u003e% of the ranking compared to a random selection\u003csup\u003e\u003cspan citationid=\"CR70\" class=\"CitationRef\"\u003e70\u003c/span\u003e,\u003cspan citationid=\"CR71\" class=\"CitationRef\"\u003e71\u003c/span\u003e\u003c/sup\u003e. The statistical metrics were calculated using the following equations:\u003cdiv id=\"Equa\" class=\"Equation\"\u003e\u003cdiv format=\"TEX\" class=\"mathdisplay\" id=\"FileID_Equa\" name=\"EquationSource\"\u003e\n$$AUC= \\sum i\\left[\\left({Se}_{i+1}\\left)\\right({Sp}_{i+1}-{Sp}_{i}\\right)\\right] \\left(1\\right)$$\u003c/div\u003e\u003c/div\u003e\u003cdiv id=\"Equb\" class=\"Equation\"\u003e\u003cdiv format=\"TEX\" class=\"mathdisplay\" id=\"FileID_Equb\" name=\"EquationSource\"\u003e\n$$BEDROC=RIE \\frac{{R}_{\\alpha }sin\\left(\\frac{\\alpha }{2}\\right) }{cosh\\left(\\frac{\\alpha }{2}\\right)-cosh\\left(\\frac{\\alpha }{2-\\alpha {R}_{\\alpha }}\\right)}+ \\frac{1}{1-{e}^{\\alpha \\left(1-{R}_{\\alpha }\\right)}}\\approx \\frac{RIE}{\\alpha }+ \\frac{1}{1- {e}^{{\\alpha }^{{\\prime }}}} \\left(2\\right)$$\u003c/div\u003e\u003c/div\u003e\u003cdiv id=\"Equc\" class=\"Equation\"\u003e\u003cdiv format=\"TEX\" class=\"mathdisplay\" id=\"FileID_Equc\" name=\"EquationSource\"\u003e\n$$if \\alpha {R}_{\\alpha }\\ll 1 and \\alpha \\ne 0$$\u003c/div\u003e\u003c/div\u003e\u003cdiv id=\"Equd\" class=\"Equation\"\u003e\u003cdiv format=\"TEX\" class=\"mathdisplay\" id=\"FileID_Equd\" name=\"EquationSource\"\u003e\n$${EF}^{x\\%}= \\frac{\\raisebox{1ex}{${Hits}^{x\\%}selected$}\\!\\left/ \\!\\raisebox{-1ex}{${N}^{x\\%}selected$}\\right. }{\\raisebox{1ex}{${Hits}_{total}$}\\!\\left/ \\!\\raisebox{-1ex}{${N}_{total}$}\\right.} \\left(3\\right)$$\u003c/div\u003e\u003c/div\u003e\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec17\" class=\"Section2\"\u003e \u003ch2\u003eSelective bias docking and post-processing with MMGBSA\u003c/h2\u003e \u003cp\u003eThe protein structures of \u003cem\u003ePlasmodium\u003c/em\u003e (PDB ID: 2YNE)\u003csup\u003e\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e\u003c/sup\u003e and \u003cem\u003eH. sapiens\u003c/em\u003e (PDB ID: 5O6J)\u003csup\u003e\u003cspan citationid=\"CR72\" class=\"CitationRef\"\u003e72\u003c/span\u003e\u003c/sup\u003e were processed in the Protein Preparation Wizard module\u003csup\u003e\u003cspan citationid=\"CR73\" class=\"CitationRef\"\u003e73\u003c/span\u003e\u003c/sup\u003e within Maestro (Schr\u0026ouml;dinger 2021-4, \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://www.schrodinger.com\u003c/span\u003e\u003cspan address=\"http://www.schrodinger.com\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003cspan type=\"Underline\" class=\"Underline\" name=\"Emphasis\"\u003e).\u003c/span\u003e This protocol includes addition of hydrogen atoms, calculation of ionization states at physiological pH (7.4\u0026thinsp;\u0026plusmn;\u0026thinsp;0.5) using the Epik program\u003csup\u003e\u003cspan citationid=\"CR74\" class=\"CitationRef\"\u003e74\u003c/span\u003e,\u003cspan citationid=\"CR75\" class=\"CitationRef\"\u003e75\u003c/span\u003e\u003c/sup\u003e, and removal of structural waters with a distance greater than 3 \u0026Aring; from the side chains. Subsequently, protein hydrogen bond assignments and protonation states were refined using PROPKA, followed by restrained minimization using the OPLS-2005 force field\u003csup\u003e\u003cspan citationid=\"CR76\" class=\"CitationRef\"\u003e76\u003c/span\u003e,\u003cspan citationid=\"CR77\" class=\"CitationRef\"\u003e77\u003c/span\u003e\u003c/sup\u003e. Ligand preparation was carried out in the LigPrep module in Maestro (Schr\u0026ouml;dinger 2021-4, \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://www.schrodinger.com\u003c/span\u003e\u003cspan address=\"http://www.schrodinger.com\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003cspan type=\"Underline\" class=\"Underline\" name=\"Emphasis\"\u003e)\u003c/span\u003e, with ionization states set at physiological pH (7.4\u0026thinsp;\u0026plusmn;\u0026thinsp;0.5) using the Epik program. Conformers were generated, retaining the stereoisomerism, and the geometry was minimized using the OPLS-2005 force field. Three-dimensional coordinates of the grid were constructed using the Receptor Grid Generation (Schr\u0026ouml;dinger 2021-4, \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://www.schrodinger.com\u003c/span\u003e\u003cspan address=\"http://www.schrodinger.com\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003cspan type=\"Underline\" class=\"Underline\" name=\"Emphasis\"\u003e)\u003c/span\u003e module at the region of the peptide binding site reported in the literature for \u003cem\u003eP. vivax\u003c/em\u003e\u003csup\u003e\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e\u003c/sup\u003e (grid coordinates x\u0026thinsp;=\u0026thinsp;24,29, y\u0026thinsp;=\u0026thinsp;43,20, z\u0026thinsp;=\u0026thinsp;64,66) and \u003cem\u003eH. sapiens\u003c/em\u003e\u003csup\u003e\u003cspan citationid=\"CR72\" class=\"CitationRef\"\u003e72\u003c/span\u003e\u003c/sup\u003e(grid coordinates x = -18,31, y\u0026thinsp;=\u0026thinsp;4,55, z = -19,80), have a size of 10 \u0026Aring;. Docking validation was performed with the Glide program\u003csup\u003e\u003cspan citationid=\"CR78\" class=\"CitationRef\"\u003e78\u003c/span\u003e\u003c/sup\u003e (Schr\u0026ouml;dinger 2021-4, \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://www.schrodinger.com\u003c/span\u003e\u003cspan address=\"http://www.schrodinger.com\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003cspan type=\"Underline\" class=\"Underline\" name=\"Emphasis\"\u003e)\u003c/span\u003e using the PvNMT dataset prepared and protein structure of PvNMT. Standard precision (SP) was utilized, employing a score function that uses an exhaustive sampling search, recommended for virtual screenings campaigns\u003csup\u003e\u003cspan citationid=\"CR79\" class=\"CitationRef\"\u003e79\u003c/span\u003e\u003c/sup\u003e. Statistical metrics including AUC, EF and BEDROC were computed using an \u003cem\u003ein-house\u003c/em\u003e workflow in KNIME\u003csup\u003e\u003cspan citationid=\"CR80\" class=\"CitationRef\"\u003e80\u003c/span\u003e\u003c/sup\u003e to assess the robustness of the docking program. The MMGBSA rescoring method was performed in the Prime module version 3.0 (Schr\u0026ouml;dinger 2021-4, \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://www.schrodinger.com\u003c/span\u003e\u003cspan address=\"http://www.schrodinger.com\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003cspan type=\"Underline\" class=\"Underline\" name=\"Emphasis\"\u003e).\u003c/span\u003e This module computes the energy of the ligand-protein complex in solvent from the initial docking poses. Rescoring was applied during protocol validation and during virtual screening for the Top 10% of the ranked list. The system was composed of implicit solvent of the VSGB2 model\u003csup\u003e\u003cspan citationid=\"CR81\" class=\"CitationRef\"\u003e81\u003c/span\u003e\u003c/sup\u003e, parametrized on OPLS-2005 force field. The hierarchical sampling method was employed, with active site residues kept rigid in the first cycle and site conformations explored in the second cycle until finding the lowest ΔG value expressed in Kcal/mol\u003csup\u003e82,83\u003c/sup\u003e.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec18\" class=\"Section2\"\u003e \u003ch2\u003eVirtual Screening\u003c/h2\u003e \u003cp\u003eFollowing the validation of shape-based models and docking, augmented by MMGBSA rescoring, the virtual screenings were carried out using the Core library and Express-Pick collection stock libraries from the ChemBridge database ( \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.chembridge.com/screening_libraries/\u003c/span\u003e\u003cspan address=\"https://www.chembridge.com/screening_libraries/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003cspan type=\"Underline\" class=\"Underline\" name=\"Emphasis\"\u003e)\u003c/span\u003e and Life Chemicals Antimalarial Screening Libraries (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://lifechemicals.com/screening-libraries/targeted-and-focused-screening-libraries/antimalarial-screening-libraries\u003c/span\u003e\u003cspan address=\"https://lifechemicals.com/screening-libraries/targeted-and-focused-screening-libraries/antimalarial-screening-libraries\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003cspan type=\"Underline\" class=\"Underline\" name=\"Emphasis\"\u003e).\u003c/span\u003e These combined libraries encompass over 1.5\u0026nbsp;million compounds in total. These data were compiled and processed following the mentioned protocol for ligand preparation. The first filter was the best shape-based model for PvNMT, where the Top 10% of the list went to the selective docking and rescoring filter between \u003cem\u003ePlasmodium\u003c/em\u003e and human NMT. The Top 10% analyzed with the MMGBSA-ΔG threshold \u0026le; -70 Kcal/mol for PvNMT and presents a difference of \u0026le; -50 Kcal/mol against HsNMT. The compounds selected in the previous step were predicted by the 3D7 and W2 malaria machine learning models(described in \u003csup\u003e\u003cspan citationid=\"CR84\" class=\"CitationRef\"\u003e84\u003c/span\u003e\u003c/sup\u003e), considering that the target is essential during the asexual blood stage. For the final selection process, cluster analysis was performed using DataWarrior software\u003csup\u003e\u003cspan citationid=\"CR85\" class=\"CitationRef\"\u003e85\u003c/span\u003e\u003c/sup\u003e to identify representative chemotypes and avoid redundancy by excluding very similar compounds. Additionally, a medicinal chemistry visual inspection of the MMGBSA pose was performed, and predictions of ADMET (Absorption, Availability, Metabolism, Excretion and Toxicology) were made using the SWISS-ADME server (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://www.swissadme.ch/\u003c/span\u003e\u003cspan address=\"http://www.swissadme.ch/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003cspan type=\"Underline\" class=\"Underline\" name=\"Emphasis\"\u003e)\u003c/span\u003e\u003csup\u003e86\u003c/sup\u003e. Finally, the prioritized candidates (See Supplementary Data file 1) were purchased and validated through \u003cem\u003ein vitro\u003c/em\u003e assays using yeast-modified strains expressing \u003cem\u003eP. vivax\u003c/em\u003e and human NMT, as well as \u003cem\u003eP. falciparum\u003c/em\u003e 3D7, Dd2 and SB1A6 strains, cytotoxicity and enzymatic assays to comprehensively evaluate the compounds' efficacy and safety profiles.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec19\" class=\"Section2\"\u003e \u003ch2\u003eMolecular Dynamics simulations\u003c/h2\u003e \u003cp\u003eThe simulations were performed in the Desmond program version 6.9\u003csup\u003e87\u003c/sup\u003e on the Maestro platform (Schr\u0026ouml;dinger 2021-4, \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://www.schrodinger.com\u003c/span\u003e\u003cspan address=\"http://www.schrodinger.com\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003cspan type=\"Underline\" class=\"Underline\" name=\"Emphasis\"\u003e).\u003c/span\u003e The system for the 300 nanoseconds simulation was built in the System Builder module and used the explicit solvent (H2O) model of the TIP3P type\u003csup\u003e\u003cspan citationid=\"CR88\" class=\"CitationRef\"\u003e88\u003c/span\u003e,\u003cspan citationid=\"CR89\" class=\"CitationRef\"\u003e89\u003c/span\u003e\u003c/sup\u003e, the periodic boundary conditions of the orthorhombic type with water buffer at 10 \u0026Aring; around the protein. Ion\u0026rsquo;s sodium (Na\u003csup\u003e+\u003c/sup\u003e) and chlorine (Cl\u003csup\u003e\u0026minus;\u003c/sup\u003e) were added to neutralize the system, whose final concentration was NaCl at 150 mM. The system was minimized in a cubic box using the OPLS4 force field\u003csup\u003e\u003cspan citationid=\"CR90\" class=\"CitationRef\"\u003e90\u003c/span\u003e\u003c/sup\u003e and the isothermal-isobaric NPT ensemble was used, in which the number of particles, pressure and temperature in the system were constant. To adjust the temperature, the Nose-Hoover thermostat\u003csup\u003e\u003cspan citationid=\"CR91\" class=\"CitationRef\"\u003e91\u003c/span\u003e\u003c/sup\u003e at 300 K, and the Martyna-Tobias-Klein barostato\u003csup\u003e\u003cspan citationid=\"CR92\" class=\"CitationRef\"\u003e92\u003c/span\u003e\u003c/sup\u003e at 1.01325 pressure was used. Data processing of Root Mean Square Deviations (RMSD), Root Mean Square Fluctuation (RMSF), and protein-ligand interactions were obtained in the Simulation Interactions Diagram module.\u003c/p\u003e \u003cp\u003eTrajectory cluster analysis was performed using the Trajectory clustering module on Maestro (Schr\u0026ouml;dinger 2021-4, \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttp://www.schrodinger.com\u003c/span\u003e\u003cspan address=\"http://www.schrodinger.com\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003cspan type=\"Underline\" class=\"Underline\" name=\"Emphasis\"\u003e)\u003c/span\u003e to obtain the most representative conformations of the lowest energy of the most populated cluster.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec20\" class=\"Section2\"\u003e \u003ch2\u003eExperimental\u003c/h2\u003e \u003cdiv id=\"Sec21\" class=\"Section3\"\u003e \u003ch2\u003eConstruction of plasmids and yeast -modified strains\u003c/h2\u003e \u003cp\u003eBy codon usage optimization for expression in \u003cem\u003eSaccharomyces cerevisiae\u003c/em\u003e, the coding sequences of NMT from \u003cem\u003eH. sapiens\u003c/em\u003e and \u003cem\u003eP. vivax\u003c/em\u003e (here referred to as HsNMT and PvNMT, respectively) were synthesized, amplified by PCR, and subsequently, cloned into the \u003cem\u003eBam\u003c/em\u003e HI-\u003cem\u003ePst\u003c/em\u003e I sites of the yeast expression vector pCM188-URA3 (EUROSCARF), resulting in the generation of the following constructs: pCM188-URA3-HsNMT and pCM188-URA3-PvNMT. For more details on these constructs, please review the publication from Bilsland, E. and colleagues\u003csup\u003e\u003cspan citationid=\"CR93\" class=\"CitationRef\"\u003e93\u003c/span\u003e\u003c/sup\u003e. The DNA constructs, verified by sequencing, were used in this work for the yeast-based functional complementation system. \u003cem\u003eS. cerevisiae\u003c/em\u003e strains and plasmids used are listed in Table\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab3\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003ePlasmids and strains used in this study.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"4\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePlasmid\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eFeatures\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eDerived from\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eSource\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003epCM188-URA3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cem\u003eCEN\u003c/em\u003e; \u003cem\u003eURA3\u003c/em\u003e; TetO2 promoter\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eEUROSCARF\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003epCM188-URA3-HsNMT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cem\u003eHomo sapiens\u003c/em\u003e NMT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003epCM188-URA3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eRef \u003csup\u003e\u003cspan citationid=\"CR74\" class=\"CitationRef\"\u003e74\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003epCM188-URA3-PvNMT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cem\u003ePlasmodium vivax\u003c/em\u003e NMT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003epCM188-URA3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eRef \u003csup\u003e\u003cspan citationid=\"CR74\" class=\"CitationRef\"\u003e74\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBY4741\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cem\u003eMATa his3∆1 leu2∆0 met15∆0 LYS2 ura3∆0\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eEUROSCARF\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003enmt1∆/NMT1\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cem\u003enmt1::KanMX/NMT1 MATa/MATα his3∆1/his3∆1 leu2∆0/leu2∆0 met15∆0/MET15 LYS2/lys2∆0 ura3∆0/ura3∆0;\u003c/em\u003e Kan/G418\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eEUROSCARF\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003enmt1∆/NMT1_p\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u003cem\u003epdr5::HISMX/PDR5 nmt1::KanMX/NMT1 MATa/MATα his3∆1/his3∆1 leu2∆0/leu2∆0 met15∆0/MET15 LYS2/lys2∆0 ura3∆0/ura3∆0;\u003c/em\u003e Kan/G418\u003c/p\u003e \u003cp\u003e\u003cem\u003eHISMX\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e\u003cem\u003enmt1∆/NMT1\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eRef \u003csup\u003e\u003cspan citationid=\"CR74\" class=\"CitationRef\"\u003e74\u003c/span\u003e\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv id=\"Sec22\" class=\"Section2\"\u003e \u003ch2\u003ePhenotypic analysis using Bioscreen\u003c/h2\u003e \u003cp\u003eYPD media (20% glucose,2% peptone, and 1% yeast extract) was used for routine culturing of strains. Frozen stocks on exponential growth phase were transferred to Falcon tubes with YPD media. Growth was maintained for an hour in a rotary shaker at 30\u0026deg;C at 200 rpm. Before the start of experiment, the medium was removed, and the pellet resuspended in new media to a final OD\u003csub\u003e600\u003c/sub\u003e of 1.0. Subsequently the cultures were diluted to an OD\u003csub\u003e600\u003c/sub\u003e of 0.1 into 100-well honeycomb plates (Labsystems Oy) pre-aliquoted with the appropriate media and tests. Strains were cultivated for 3 days with the low shaking setting at 30\u0026deg;C with 20 minutes measurement intervals using a wide band filter (450 to 600 nm) using Bioscreen C (Labsystems Oy). At the end of the experiment, the data were treated and normalized in the PRECOG program\u003csup\u003e\u003cspan citationid=\"CR94\" class=\"CitationRef\"\u003e94\u003c/span\u003e\u003c/sup\u003e. Then an R script was used using a growth curve library, to compute the cell yield (K) values, which was the parameter that best fits the data\u003csup\u003e\u003cspan citationid=\"CR95\" class=\"CitationRef\"\u003e95\u003c/span\u003e\u003c/sup\u003e. The data was subsequently exported to the GraphPad Prism 9 program, and the growth of tests and control growth were analyzed by the non-linear logistic regression model.\u003c/p\u003e \u003cdiv id=\"Sec23\" class=\"Section3\"\u003e \u003ch2\u003ePhenotypic antimalarial assays\u003c/h2\u003e \u003cp\u003eThe antimalarial activity assay was assessed on \u003cem\u003eP. falciparum\u003c/em\u003e 3D7 (chloroquine-sensitive), Dd2 (chloroquine-resistant) and SB1 (atovaquone-resistant) strains\u003csup\u003e\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e\u003c/sup\u003e. The parasites were cultivated in RPMI 1640 medium (SIGMA-ALDRICH), supplemented with hypoxanthine 0.005%, glucose 0.2%, sodium bicarbonate 0.2%, O\u003csup\u003e+\u003c/sup\u003e red blood cells (RBCs) and A\u003csup\u003e+\u003c/sup\u003e human plasma 10%. The cultures were incubated at 37\u0026deg;C in a low oxygen environment (3% O2, 5% CO2, and 92% N2) as described by Trager et al.\u003csup\u003e\u003cspan citationid=\"CR96\" class=\"CitationRef\"\u003e96\u003c/span\u003e\u003c/sup\u003e Drug inhibition assays were performed as previously described\u003csup\u003e\u003cspan citationid=\"CR97\" class=\"CitationRef\"\u003e97\u003c/span\u003e\u003c/sup\u003e. Briefly, synchronizations with 5% D-Sorbitol solution were performed at 48-hour intervals before experiments to allow incubations with \u0026gt;\u0026thinsp;90% of the parasites in the ring stage. Assays were performed in a 96-well plate, with 0.5% parasitemia and 2% hematocrit, in the presence of 5 \u0026micro;M of compounds or the drug vehicle (DMSO), as a control. Artesunate was used as an antimalarial standard. After 72 hours of incubation, parasitemia was assessed by fluorometry using SybrGreen fluorescent dye\u003csup\u003e\u003cspan citationid=\"CR98\" class=\"CitationRef\"\u003e98\u003c/span\u003e\u003c/sup\u003e. The plates were read in a CLARIOStar plate reader (BGMtech) by fluorescence at 490 nm excitation and 540 nm emission wavelengths. The growth inhibition values were expressed as percentages relative to the drug-free control, and EC\u003csub\u003e50\u003c/sub\u003e values were calculated by plotting Log dosing vs growth inhibition (expressed as percentages relative to the drug-free control) using GraphPad Prism 8. The experiments were carried out in three independent assays.\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv id=\"Sec24\" class=\"Section2\"\u003e \u003ch2\u003eHemolysis assay\u003c/h2\u003e \u003cp\u003eThe hemolysis assay was carried out according to Wang et al. (2010)\u003csup\u003e\u003cspan citationid=\"CR99\" class=\"CitationRef\"\u003e99\u003c/span\u003e\u003c/sup\u003e with modifications. Suspensions of erythrocytes (2% hematocrit) were incubated with the compounds at 20 \u0026micro;M or the drug vehicle (DMSO), as a control, at 37\u0026deg;C, 5% CO\u003csub\u003e2\u003c/sub\u003e, for 4 hours. The reaction mixtures were centrifuged at 1000g for 5 minutes, and the absorbance of the supernatants was measured at 540 nm using a Biotek Synergy-HT spectrophotometer. The hemolytic rate was calculated in relation to the hemolysis of erythrocytes in 1% of Triton X100, which was taken as 100%, using GraphPad Prism 8. The experiments were carried out in triplicate, relative to two independent assays.\u003c/p\u003e \u003cdiv id=\"Sec25\" class=\"Section3\"\u003e \u003ch2\u003eCytotoxicity assays\u003c/h2\u003e \u003cp\u003eThe cytotoxicity was evaluated using the MTT (3-[4,5-dimethyl-thiazol-2-yl]-2,5-diphenyltetrazolium chloride) reduction assay for quantification of cellular reductase enzymes activity as an indirect measurement of cell viability using human hepatocarcinoma cell line (HepG-2) and fibroblast-like cell lines derived from monkey kidney tissue (COS-7 cells\u003csup\u003e\u003cspan citationid=\"CR100\" class=\"CitationRef\"\u003e100\u003c/span\u003e\u003c/sup\u003e). Briefly, the cells were cultured in Dulbecco's Modified Eagle Medium supplemented with 10% heat-inactivated fetal bovine serum and 1% antibiotic-antimycotic solution (10,000 UI of penicillin, 10 mg of streptomycin in 0.9% sodium chloride; Sigma Chemical Co., Saint Louis, USA) at 37\u0026deg;C and 5% CO\u003csub\u003e2\u003c/sub\u003e. The assays were conducted in a 96-well plate at a density of 10\u003csup\u003e4\u003c/sup\u003e cells per well. The cells were then incubated with a serial dilution of the drugs, starting at 100 \u0026micro;M, along with non-treated controls, for 72 hours. After the drug treatment, MTT was added to the wells, and absorbance readings were obtained using a CLARIOStar plate reader (BGMtech) at a wavelength of 570 nm (OD570). Cellular viability was expressed as a percentage relative to the vehicle-treated control. The CC\u003csub\u003e50\u003c/sub\u003e was calculated by plotting a log dose vs. viability curve using GraphPad Prism 8. The experiments were performed in two independent assays.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec26\" class=\"Section3\"\u003e \u003ch2\u003eEnzymatic assays\u003c/h2\u003e \u003cp\u003eTo measure the activity of the purified PvNMT, an activity assay was adapted from Goncalves et al, 2012\u003csup\u003e101\u003c/sup\u003e. A fresh stock of 4x assay buffer was made consisting of 9.2 mM potassium phosphate (KH\u003csub\u003e2\u003c/sub\u003ePO\u003csub\u003e4\u003c/sub\u003e), 69.7 mM sodium phosphate (Na\u003csub\u003e2\u003c/sub\u003eHPO\u003csub\u003e4\u003c/sub\u003e), 2 mM EDTA, and 0.04% TritonX-100 at pH 7.0. Fresh working stock solutions were made by adding DMSO for a final concentration of 1% or 5% and a concentration of 1x assay buffer. Another working stock solution was made by adding DMSO for a final concentration of 10%, without assay buffer. The test compound solutions were made from the 20 mM stock. The test compounds were diluted in 10% DMSO to make a 10mM stock. From the 10 mM stock, the test compounds were further diluted into 20 \u0026micro;M and 2 \u0026micro;M stocks in 10% DMSO. A 10 \u0026micro;M stock of a control inhibitor, known as Control 02(DDD85646), was made, and then further diluted in 10% DMSO to make a 2 \u0026micro;M solution. 10 \u0026micro;L of the test compounds were plated in triplicates in a black, closed bottom 96-well plate (Greiner Bio-One). For the negative and positive control, 10 \u0026micro;L of 10% DMSO was plated in quadruplicates. 10 \u0026micro;L of the control inhibitor, Control 02, was plated in quadruplicates. The PvNMT protein was diluted in 1% DMSO containing 1x assay buffer for a final concentration of 10 \u0026micro;M. The PvNMT protein was diluted further in 1% DMSO, and 50 \u0026micro;L was added to each well in the 96-well plate for a final PvNMT concentration of 25 nM. For the negative control, 50 \u0026micro;L of 1% DMSO containing 1x assay buffer was added to the well instead of the PvNMT protein. The reaction was initiated by adding 50 \u0026micro;L of reaction substrate containing 10 \u0026micro;M PfARF (Gly-Leu-Tyr-Val-Ser-Arg-Leu-Phe-Asn-Arg-Leu-Phe-Gln-Lys-Lys-NH2 purchased from Innopep in San Diego, California), 10 \u0026micro;M Myr-CoA (myristoyl coenzyme A purchased from purchased from Med Chem 101 LLC in Plymouth Meeting, Pennsylvania), and 8 \u0026micro;M CPM (7-Diethylamino-3-(4'-Maleimidylphenyl)-4-Methylcoumarin purchased from Thermo Scientific Life Technologies in Grand Island, New York) to each well. Fluorescent readings were immediately taken of the plate using Spectra M2 plate reader (Molecular Devices) with excitation at 385 nm and emission at 485 nm. Reading continuously were taken in one-minute intervals for 45 minutes. Background fluorescence and noise were determined by replacing each constituent of the reaction individually with 1% DMSO containing 1x assay buffer, and values were deducted from experimental samples. The percent inhibition of each test compound was calculated using Prism (GraphPad Software, Inc).\u003c/p\u003e \u003c/div\u003e"},{"header":"Declarations","content":"\u003cdiv id=\"Sec27\" class=\"Section3\"\u003e\n \u003cp\u003e\u003cstrong\u003eData availability\u003c/strong\u003e\u003c/p\u003e\n \u003cp\u003eThe docked structures, MD simulation trajectories data are available as free download at \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.5281/zenodo.10477925\u003c/span\u003e\u003c/span\u003e. Protein expression plasmids of \u003cem\u003ePv\u003c/em\u003eNMT and \u003cem\u003eHs\u003c/em\u003eNMT1 and \u003cem\u003eHs\u003c/em\u003eNMT2 are available at \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.ssgcid.org/available-materials/ssgcid-proteins/\u003c/span\u003e\u003c/span\u003e through material transfer agreement (MTA). All additional data are available from the corresponding authors on reasonable request.\u003c/p\u003e\n\u003c/div\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowledgments\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eBKPS was supported by fellowships from Brazilian agencies CNPq (process 142059/2020-0), and CAPES-STINT project number 88887.304810/2018-00.\u0026nbsp;This study was financed in part by the Coordena\u0026ccedil;\u0026atilde;o de Aperfei\u0026ccedil;oamento de Pessoal de N\u0026iacute;vel Superior \u0026ndash; Brasil (CAPES) \u0026ndash; Finance Code 001.\u0026nbsp;This work has been funded by\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003eCNPq BRICS STI COVID-19 (#441038/2020-4), FAPEG (#202010267000272), S\u0026atilde;o Paulo Research Foundation (FAPESP grants #2020/06190-0, #2021/10084-3, #2021/13237-5 and #2020/05369-6). CHA and FTMC are CNPq research fellows. FTMC thanks the Funda\u0026ccedil;\u0026atilde;o de Amparo \u0026agrave; Pesquisa do Estado de S\u0026atilde;o Paulo (FAPESP) grant numbers 2017/18611\u0026ndash;7 and 2018/07007\u0026ndash;4. LCS was funded by FAPESP (process 2023/07805-6). The authors thank the Swedish Research Council (VR), grant numbers 2019-3684 and 2021-03667, and the Swedish Foundation for International Cooperation in Research and Higher Education (STINT), grant number BR2018-8017. \u0026nbsp;The computations were enabled by resources provided by the National Academic Infrastructure for Supercomputing in Sweden (NAISS) and the Swedish National Infrastructure for Computing (SNIC) at Tetralith and Vera supercomputers, partially funded by the Swedish Research Council through grant agreements no. 2022-06725 and no. 2018-05973. This project has been funded in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, to support the Seattle Structural Genomics Center for Infectious Disease (SSGCID) under Contract No. HHSN272201700059C. (BLS, SG, MK, RZ). Research reported in this publication was supported by the National Institute for Allergy and Infectious Disease of the National Institutes of Health under award number R01AI155536 (BLS). We are grateful to OpenEye Scientific Software Inc. (https:// www.eyesopen.com/) for providing academic license of their programs.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthor contributions\u003c/strong\u003e.\u003c/p\u003e\n\u003cp\u003eEach author has contributed significantly to this work. BKPS conducted the in silico experiments, which involved developing shape-based models, docking models, conducting virtual screening, and performing molecular dynamics simulations. JVVB filtered compounds through the QSAR malaria models. BKPS and SSS performed the yeast-based assays. LCC and LCS performed the malaria phenotypic, hemolysis assay and cytotoxicity assays. \u0026nbsp;RZ, MK and SG conducted the NMT enzymatic assays. BKPS drafted the manuscript and all authors contributed additions and corrections. CB, PS, LAE, FTCM, BS and CA revised the paper. All authors read, edited, and approved the final manuscript.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eOpen access funding provided by University of Gothenburg.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declare no competing interests.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAdditional information\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eSupplementary information:\u0026nbsp;\u003c/strong\u003eThe online version contains supplementary materials available at link to be provided.\u0026nbsp;\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003ePhillips, M. A. \u003cem\u003eet al.\u003c/em\u003e Malaria. \u003cem\u003eNat. Rev. Dis. Prim.\u003c/em\u003e \u003cstrong\u003e3\u003c/strong\u003e, 17050 (2017).\u003c/li\u003e\n\u003cli\u003eOrganiza\u0026ccedil;\u0026atilde;o Mundial da Sa\u0026uacute;de. World Malaria Report 2023. \u003cem\u003eWorld Health\u003c/em\u003e WHO/HTM/GM, \u003cstrong\u003e238 \u003c/strong\u003e(2023).\u003c/li\u003e\n\u003cli\u003eHowes, R. E. \u003cem\u003eet al.\u003c/em\u003e Global epidemiology of Plasmodium vivax. \u003cem\u003eAm. J. Trop. Med. Hyg.\u003c/em\u003e \u003cstrong\u003e95\u003c/strong\u003e, 15\u0026ndash;34 (2016).\u003c/li\u003e\n\u003cli\u003eMinist\u0026eacute;rio da Sa\u0026uacute;de. Secretaria de Vigil\u0026acirc;ncia em Sa\u0026uacute;de.Brasil. Boletim Epidemiol\u0026oacute;gico. \u003cstrong\u003e55\u003c/strong\u003e, (2024).\u003c/li\u003e\n\u003cli\u003eMikolajczak, S. A. \u003cem\u003eet al.\u003c/em\u003e Plasmodium vivax liver stage development and hypnozoite persistence in human liver-chimeric mice. \u003cem\u003eCell Host Microbe\u003c/em\u003e \u003cstrong\u003e17\u003c/strong\u003e, 526\u0026ndash;535 (2015).\u003c/li\u003e\n\u003cli\u003eKrotoski, W. A. \u003cem\u003eet al.\u003c/em\u003e Demonstration of Hypnozoites in Sporozoite-Transmitted Plasmodium vivax Infection. \u003cem\u003eAm. J. Trop. Med. Hyg.\u003c/em\u003e \u003cstrong\u003e31\u003c/strong\u003e, 1291\u0026ndash;1293 (1982).\u003c/li\u003e\n\u003cli\u003eDemb\u0026eacute;l\u0026eacute;, L. \u003cem\u003eet al.\u003c/em\u003e Persistence and activation of malaria hypnozoites in long-term primary hepatocyte cultures. \u003cem\u003eNat. Med. 2014 203\u003c/em\u003e \u003cstrong\u003e20\u003c/strong\u003e, 307\u0026ndash;312 (2014).\u003c/li\u003e\n\u003cli\u003eTaylor, A. R. \u003cem\u003eet al.\u003c/em\u003e Resolving the cause of recurrent Plasmodium vivax malaria probabilistically. \u003cem\u003eNat. Commun. 2019 101\u003c/em\u003e \u003cstrong\u003e10\u003c/strong\u003e, 1\u0026ndash;11 (2019).\u003c/li\u003e\n\u003cli\u003eKitchen, S. F. The Infection of Reticulocytes by Plasmodium Vivax 1. \u003cem\u003eAm. J. Trop. Med. Hyg.\u003c/em\u003e \u003cstrong\u003es1\u003c/strong\u003e-\u003cstrong\u003e18\u003c/strong\u003e, 347\u0026ndash;359 (1938).\u003c/li\u003e\n\u003cli\u003eClark, M. A. \u003cem\u003eet al.\u003c/em\u003e Plasmodium vivax infection compromises reticulocyte stability. \u003cem\u003eNat. Commun.\u003c/em\u003e \u003cstrong\u003e12\u003c/strong\u003e, 1\u0026ndash;11 (2021).\u003c/li\u003e\n\u003cli\u003eKitchen, S. F. \u0026amp; Boyd, M. F. On the Infectiousness of Patients Infected with Plasmodium Vivax and Plasmodium Falciparum 1. \u003cem\u003eAm. J. Trop. Med. Hyg.\u003c/em\u003e \u003cstrong\u003es1\u003c/strong\u003e-\u003cstrong\u003e17\u003c/strong\u003e, 253\u0026ndash;262 (1937).\u003c/li\u003e\n\u003cli\u003eBousema, T. \u0026amp; Drakeley, C. Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. \u003cem\u003eClinical Microbiology Reviews\u003c/em\u003e vol. 24 377\u0026ndash;410 (2011).\u003c/li\u003e\n\u003cli\u003eGon\u0026ccedil;alves, L. A., Cravo, P. \u0026amp; Ferreira, M. U. Emerging Plasmodium vivax resistance to chloroquine in South America: An overview. \u003cem\u003eMem. Inst. Oswaldo Cruz\u003c/em\u003e \u003cstrong\u003e109\u003c/strong\u003e, 534\u0026ndash;539 (2014).\u003c/li\u003e\n\u003cli\u003eWellems, T. E. \u0026amp; Plowe, C. V. Chloroquine‐Resistant Malaria. \u003cem\u003eJ. Infect. Dis.\u003c/em\u003e \u003cstrong\u003e184\u003c/strong\u003e, 770\u0026ndash;776 (2001).\u003c/li\u003e\n\u003cli\u003eS\u0026aacute;, J. M. \u003cem\u003eet al.\u003c/em\u003e Plasmodium vivax chloroquine resistance links to pvcrt transcription in a genetic cross. \u003cem\u003eNat. Commun. 2019 101\u003c/em\u003e \u003cstrong\u003e10\u003c/strong\u003e, 1\u0026ndash;10 (2019).\u003c/li\u003e\n\u003cli\u003eWorld Health Organization. World Malaria Report 2015 - World Health Organization. https://www.who.int/publications/i/item/9789241565158 (2015).\u003c/li\u003e\n\u003cli\u003eFerreira, M. U. \u003cem\u003eet al.\u003c/em\u003e Monitoring Plasmodium vivax resistance to antimalarials: Persisting challenges and future directions. \u003cem\u003eInt. J. Parasitol. Drugs Drug Resist.\u003c/em\u003e \u003cstrong\u003e15\u003c/strong\u003e, 9\u0026ndash;24 (2021).\u003c/li\u003e\n\u003cli\u003eBhatnagar, R. S. \u003cem\u003eet al.\u003c/em\u003e Structure of N-myristoyltransferase with bound myristoylCoA and peptide substrate analogs. \u003cem\u003eNat. Struct. Biol.\u003c/em\u003e \u003cstrong\u003e5\u003c/strong\u003e, 1091\u0026ndash;1097 (1998).\u003c/li\u003e\n\u003cli\u003eThinon, E., Morales-Sanfrutos, J., Mann, D. J. \u0026amp; Tate, E. W. N-Myristoyltransferase Inhibition Induces ER-Stress, Cell Cycle Arrest, and Apoptosis in Cancer Cells. \u003cem\u003eACS Chem. Biol.\u003c/em\u003e \u003cstrong\u003e11\u003c/strong\u003e, 2165\u0026ndash;2176 (2016).\u003c/li\u003e\n\u003cli\u003eKarki, R. G. \u0026amp; Kulkarni, V. M. A feature based pharmacophore for Candida albicans MyristoylCoA: protein N-myristoyltransferase inhibitors. \u003cem\u003eEur. J. Med. Chem.\u003c/em\u003e \u003cstrong\u003e36\u003c/strong\u003e, 147\u0026ndash;163 (2001).\u003c/li\u003e\n\u003cli\u003eFrearson, J. A. \u003cem\u003eet al.\u003c/em\u003e N-myristoyltransferase inhibitors as new leads to treat sleeping sickness. \u003cem\u003eNature\u003c/em\u003e \u003cstrong\u003e464\u003c/strong\u003e, 728\u0026ndash;732 (2010).\u003c/li\u003e\n\u003cli\u003eHerrera, L. J. \u003cem\u003eet al.\u003c/em\u003e Validation of N-myristoyltransferase as Potential Chemotherapeutic Target in Mammal-Dwelling Stages of Trypanosoma cruzi. \u003cem\u003ePLoS Negl. Trop. Dis.\u003c/em\u003e \u003cstrong\u003e10\u003c/strong\u003e, e0004540 (2016).\u003c/li\u003e\n\u003cli\u003eOlaleye, T. O. \u003cem\u003eet al.\u003c/em\u003e Peptidomimetic inhibitors of N-myristoyltransferase from human malaria and leishmaniasis parasites. \u003cem\u003eOrg. Biomol. Chem.\u003c/em\u003e \u003cstrong\u003e12\u003c/strong\u003e, 8132\u0026ndash;8137 (2014).\u003c/li\u003e\n\u003cli\u003eRackham, M. D. \u003cem\u003eet al.\u003c/em\u003e Discovery of high affinity inhibitors of Leishmania donovani N-myristoyltransferase. \u003cem\u003eMedchemcomm\u003c/em\u003e \u003cstrong\u003e6\u003c/strong\u003e, 1761\u0026ndash;1766 (2015).\u003c/li\u003e\n\u003cli\u003eFenwick, M. K. \u003cem\u003eet al.\u003c/em\u003e Identification of and Structural Insights into Hit Compounds Targeting N-Myristoyltransferase for Cryptosporidium Drug Development. \u003cem\u003eACS Infect. Dis.\u003c/em\u003e \u003cstrong\u003e9\u003c/strong\u003e, 1821\u0026ndash;1833 (2023).\u003c/li\u003e\n\u003cli\u003eBell, A. S. \u003cem\u003eet al.\u003c/em\u003e Selective inhibitors of protozoan protein N-myristoyltransferases as starting points for tropical disease medicinal chemistry programs. \u003cem\u003ePLoS Negl. Trop. Dis.\u003c/em\u003e \u003cstrong\u003e6\u003c/strong\u003e, (2012).\u003c/li\u003e\n\u003cli\u003eTate, E. W., Bell, A. S., Rackham, M. D. \u0026amp; Wright, M. H. N-Myristoyltransferase as a potential drug target in malaria and leishmaniasis. \u003cem\u003eParasitology\u003c/em\u003e \u003cstrong\u003e141\u003c/strong\u003e, 37\u0026ndash;49 (2014).\u003c/li\u003e\n\u003cli\u003eSchlott, A. C., Holder, A. A. \u0026amp; Tate, E. W. N -Myristoylation as a Drug Target in Malaria: Exploring the Role of N -Myristoyltransferase Substrates in the Inhibitor Mode of Action. \u003cem\u003eACS Infectious Diseases\u003c/em\u003e vol. 4 449\u0026ndash;457 (2018).\u003c/li\u003e\n\u003cli\u003eZhao, C. \u0026amp; Ma, S. Recent Advances in The Discovery of N-Myristoyltransferase Inhibitors. \u003cem\u003eChemMedChem\u003c/em\u003e \u003cstrong\u003e9\u003c/strong\u003e, 2425\u0026ndash;2437 (2014).\u003c/li\u003e\n\u003cli\u003eWright, M. H. \u003cem\u003eet al.\u003c/em\u003e Validation of N-myristoyltransferase as an antimalarial drug target using an integrated chemical biology approach. \u003cem\u003eNat. Chem.\u003c/em\u003e \u003cstrong\u003e6\u003c/strong\u003e, 112\u0026ndash;121 (2014).\u003c/li\u003e\n\u003cli\u003eRodr\u0026iacute;guez-Hern\u0026aacute;ndez, D. \u003cem\u003eet al.\u003c/em\u003e Identification of potent and selective N-myristoyltransferase inhibitors of Plasmodium vivax liver stage hypnozoites and schizonts. \u003cem\u003eNat. Commun.\u003c/em\u003e \u003cstrong\u003e14\u003c/strong\u003e, (2023).\u003c/li\u003e\n\u003cli\u003eKatsuno, K. \u003cem\u003eet al.\u003c/em\u003e Hit and lead criteria in drug discovery for infectious diseases of the developing world. \u003cem\u003eNat. Rev. Drug Discov. 2015 1411\u003c/em\u003e \u003cstrong\u003e14\u003c/strong\u003e, 751\u0026ndash;758 (2015).\u003c/li\u003e\n\u003cli\u003eSiqueira-Neto, J. L. \u003cem\u003eet al.\u003c/em\u003e nature reviews drug discovery Antimalarial drug discovery: progress and approaches. \u003cem\u003eNat. Rev. Drug Discov. |\u003c/em\u003e \u003cstrong\u003e22\u003c/strong\u003e, 807\u0026ndash;826 (2023).\u003c/li\u003e\n\u003cli\u003eYang, T. \u003cem\u003eet al.\u003c/em\u003e MalDA, Accelerating Malaria Drug Discovery. \u003cem\u003eTrends in Parasitology\u003c/em\u003e vol. 37 493\u0026ndash;507 (2021).\u003c/li\u003e\n\u003cli\u003eRackham, M. D. \u003cem\u003eet al.\u003c/em\u003e Discovery of Novel and Ligand-Efficient Inhibitors of Plasmodium falciparum and Plasmodium vivax N -Myristoyltransferase. \u003cem\u003eJ. Med. Chem.\u003c/em\u003e \u003cstrong\u003e56\u003c/strong\u003e, 371\u0026ndash;375 (2013).\u003c/li\u003e\n\u003cli\u003eMasubuchi, M. \u003cem\u003eet al.\u003c/em\u003e Synthesis and biological activities of benzofuran antifungal agents targeting fungal N-myristoyltransferase. \u003cem\u003eBioorg. Med. Chem.\u003c/em\u003e \u003cstrong\u003e11\u003c/strong\u003e, 4463\u0026ndash;4478 (2003).\u003c/li\u003e\n\u003cli\u003eBrand, S. \u003cem\u003eet al.\u003c/em\u003e Discovery of a novel class of orally active trypanocidal N-Myristoyltransferase inhibitors. \u003cem\u003eJ. Med. Chem.\u003c/em\u003e \u003cstrong\u003e55\u003c/strong\u003e, 140\u0026ndash;152 (2012).\u003c/li\u003e\n\u003cli\u003eHarupa, A. \u003cem\u003eet al.\u003c/em\u003e Identification of Selective Inhibitors of Plasmodium N-Myristoyltransferase by High-Throughput Screening. \u003cem\u003eJ. Med. Chem.\u003c/em\u003e \u003cstrong\u003e63\u003c/strong\u003e, 591\u0026ndash;600 (2020).\u003c/li\u003e\n\u003cli\u003eBilsland, E. \u003cem\u003eet al.\u003c/em\u003e Yeast-based automated high-throughput screens to identify anti-parasitic lead compounds. \u003cem\u003eOpen Biol.\u003c/em\u003e \u003cstrong\u003e3\u003c/strong\u003e, (2013).\u003c/li\u003e\n\u003cli\u003eSchlott, A. C. \u003cem\u003eet al.\u003c/em\u003e Structure-Guided Identification of Resistance Breaking Antimalarial N‑Myristoyltransferase Inhibitors. \u003cem\u003eCell Chem. Biol.\u003c/em\u003e \u003cstrong\u003e26\u003c/strong\u003e, 991-1000.e7 (2019).\u003c/li\u003e\n\u003cli\u003eBraga, R. C. \u0026amp; Andrade, C. H. Assessing the performance of 3D pharmacophore models in virtual screening: how good are they? \u003cem\u003eCurr. Top. Med. Chem.\u003c/em\u003e \u003cstrong\u003e13\u003c/strong\u003e, 1127\u0026ndash;1138 (2013).\u003c/li\u003e\n\u003cli\u003eNeves, B. J. \u003cem\u003eet al.\u003c/em\u003e Best Practices for Docking-Based Virtual Screening. in \u003cem\u003eMolecular Docking for Computer-Aided Drug Design: Fundamentals, Techniques, Resources and Applications\u003c/em\u003e 75\u0026ndash;98 (Academic Press, 2021). doi:10.1016/B978-0-12-822312-3.00001-1.\u003c/li\u003e\n\u003cli\u003eGoncalves, V. \u003cem\u003eet al.\u003c/em\u003e Discovery of plasmodium vivax N -myristoyltransferase inhibitors: Screening, synthesis, and structural characterization of their binding mode. \u003cem\u003eJ. Med. Chem.\u003c/em\u003e \u003cstrong\u003e55\u003c/strong\u003e, 3578\u0026ndash;3582 (2012).\u003c/li\u003e\n\u003cli\u003eSchousboe, M. L. \u003cem\u003eet al.\u003c/em\u003e Multiple Origins of Mutations in the mdr1 Gene\u0026mdash;A Putative Marker of Chloroquine Resistance in P. vivax. \u003cem\u003ePLoS Negl. Trop. Dis.\u003c/em\u003e \u003cstrong\u003e9\u003c/strong\u003e, 1\u0026ndash;17 (2015).\u003c/li\u003e\n\u003cli\u003eBorges, S. \u003cem\u003eet al.\u003c/em\u003e Genomewide scan reveals amplification of mdr1 as a common denominator of resistance to mefloquine, lumefantrine, and artemisinin in Plasmodium chabaudi malaria parasites. \u003cem\u003eAntimicrob. Agents Chemother.\u003c/em\u003e \u003cstrong\u003e55\u003c/strong\u003e, 4858\u0026ndash;4865 (2011).\u003c/li\u003e\n\u003cli\u003eKlokouzas, A. \u003cem\u003eet al.\u003c/em\u003e Plasmodium falciparum expresses a multidrug resistance-associated protein. \u003cem\u003eBiochem. Biophys. Res. Commun.\u003c/em\u003e \u003cstrong\u003e321\u003c/strong\u003e, 197\u0026ndash;201 (2004).\u003c/li\u003e\n\u003cli\u003eKatzmann, D. J., Burnett, P. E., Golin, J., Mah\u0026eacute;, Y. \u0026amp; Moye-Rowley, W. S. Transcriptional control of the yeast PDR5 gene by the PDR3 gene product. \u003cem\u003eMol. Cell. Biol.\u003c/em\u003e \u003cstrong\u003e14\u003c/strong\u003e, 4653\u0026ndash;4661 (1994).\u003c/li\u003e\n\u003cli\u003eMohasin, M. \u003cem\u003eet al.\u003c/em\u003e A Review on Synthesis and Biological Applications of Quinoline Derivative as Fused Aromatic Compounds. \u003cem\u003ePolycycl. Aromat. Compd.\u003c/em\u003e 1\u0026ndash;30 (2023) doi:10.1080/10406638.2023.2270118.\u003c/li\u003e\n\u003cli\u003eHerraiz, T., Guill\u0026eacute;n, H., Gonz\u0026aacute;lez-Pe\u0026ntilde;a, D. \u0026amp; Ar\u0026aacute;n, V. J. Antimalarial Quinoline Drugs Inhibit \u0026beta;-Hematin and Increase Free Hemin Catalyzing Peroxidative Reactions and Inhibition of Cysteine Proteases. \u003cem\u003eSci. Rep.\u003c/em\u003e \u003cstrong\u003e9\u003c/strong\u003e, 1\u0026ndash;16 (2019).\u003c/li\u003e\n\u003cli\u003eBaragana, B. \u003cem\u003eet al.\u003c/em\u003e Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy. \u003cem\u003eJ. Med. Chem.\u003c/em\u003e \u003cstrong\u003e59\u003c/strong\u003e, 9672\u0026ndash;9685 (2016).\u003c/li\u003e\n\u003cli\u003eMcCarthy, J. S. \u003cem\u003eet al.\u003c/em\u003e A Phase 1, Placebo-controlled, Randomized, Single Ascending Dose Study and a Volunteer Infection Study to Characterize the Safety, Pharmacokinetics, and Antimalarial Activity of the Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048 . \u003cem\u003eClin. Infect. Dis.\u003c/em\u003e \u003cstrong\u003e71\u003c/strong\u003e, e657\u0026ndash;e664 (2020).\u003c/li\u003e\n\u003cli\u003eMerck Healthcare. Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2). https://clinicaltrials.gov/study/NCT05974267 (2023).\u003c/li\u003e\n\u003cli\u003eMerck Healthcare. Phase IIa Proof of Concept Study of M5717-Pyronaridine in Adults and Adolescents With Acute Uncomplicated Plasmodium Falciparum Malaria (CAPTURE 1). https://clinicaltrials.gov/study/NCT05689047 (2023).\u003c/li\u003e\n\u003cli\u003eSkj\u0026aelig;rven, L., Yao, X.-Q., Scarabelli, G. \u0026amp; Grant, B. J. Integrating protein structural dynamics and evolutionary analysis with Bio3D. \u003cem\u003eBMC Bioinforma. 2014 151\u003c/em\u003e \u003cstrong\u003e15\u003c/strong\u003e, 1\u0026ndash;11 (2014).\u003c/li\u003e\n\u003cli\u003eGrant, B. J., Skj\u0026aelig;rven, L. \u0026amp; Yao, X. Q. The Bio3D packages for structural bioinformatics. \u003cem\u003eProtein Sci.\u003c/em\u003e \u003cstrong\u003e30\u003c/strong\u003e, 20\u0026ndash;30 (2021).\u003c/li\u003e\n\u003cli\u003eYu, Z. \u003cem\u003eet al.\u003c/em\u003e Design and synthesis of inhibitors of plasmodium falciparum N -myristoyltransferase, a promising target for antimalarial drug discovery. \u003cem\u003eJ. Med. Chem.\u003c/em\u003e \u003cstrong\u003e55\u003c/strong\u003e, 8879\u0026ndash;8890 (2012).\u003c/li\u003e\n\u003cli\u003eVel\u0026aacute;zquez-Libera, J. L., Dur\u0026aacute;n-Verdugo, F., Vald\u0026eacute;s-Jim\u0026eacute;nez, A., N\u0026uacute;\u0026ntilde;ez-Vivanco, G. \u0026amp; Caballero, J. LigRMSD: a web server for automatic structure matching and RMSD calculations among identical and similar compounds in protein-ligand docking. \u003cem\u003eBioinformatics\u003c/em\u003e \u003cstrong\u003e36\u003c/strong\u003e, 2912\u0026ndash;2914 (2020).\u003c/li\u003e\n\u003cli\u003eGoncalves, V. \u003cem\u003eet al.\u003c/em\u003e A fluorescence-based assay for N-myristoyltransferase activity. \u003cem\u003eAnal. Biochem.\u003c/em\u003e \u003cstrong\u003e421\u003c/strong\u003e, 342\u0026ndash;344 (2012).\u003c/li\u003e\n\u003cli\u003eGoncalves, V. \u003cem\u003eet al.\u003c/em\u003e Structure-guided optimization of quinoline inhibitors of Plasmodium N-myristoyltransferase. \u003cem\u003eMedchemcomm\u003c/em\u003e \u003cstrong\u003e8\u003c/strong\u003e, 191\u0026ndash;197 (2017).\u003c/li\u003e\n\u003cli\u003eFourches, D., Muratov, E. \u0026amp; Tropsha, A. Trust, but verify: On the importance of chemical structure curation in cheminformatics and QSAR modeling research. \u003cem\u003eJ. Chem. Inf. Model.\u003c/em\u003e \u003cstrong\u003e50\u003c/strong\u003e, 1189\u0026ndash;1204 (2010).\u003c/li\u003e\n\u003cli\u003eFourches, D., Muratov, E. \u0026amp; Tropsha, A. Trust, but Verify II: A Practical Guide to Chemogenomics Data Curation. \u003cem\u003eJ. Chem. Inf. Model.\u003c/em\u003e \u003cstrong\u003e56\u003c/strong\u003e, 1243\u0026ndash;1252 (2016).\u003c/li\u003e\n\u003cli\u003eO\u0026rsquo;Boyle, N. M. \u003cem\u003eet al.\u003c/em\u003e Open Babel: An open chemical toolbox. \u003cem\u003eJ. Cheminformatics 2011 31\u003c/em\u003e \u003cstrong\u003e3\u003c/strong\u003e, 1\u0026ndash;14 (2011).\u003c/li\u003e\n\u003cli\u003eFriedrich, N. O. \u003cem\u003eet al.\u003c/em\u003e Benchmarking Commercial Conformer Ensemble Generators. \u003cem\u003eJ. Chem. Inf. Model.\u003c/em\u003e \u003cstrong\u003e57\u003c/strong\u003e, 2719\u0026ndash;2728 (2017).\u003c/li\u003e\n\u003cli\u003eJakalian, A., Bush, B. L., Jack, D. B. \u0026amp; Bayly, C. I. Fast, Efficient Generation of High-Quality Atomic Charges. AM1-BCC Model: I. Method. \u003cem\u003eJ. Comput. Chem.\u003c/em\u003e \u003cstrong\u003e21\u003c/strong\u003e, 132\u0026ndash;146 (2000).\u003c/li\u003e\n\u003cli\u003eJakalian, A., Jack, D. B. \u0026amp; Bayly, C. I. Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation. \u003cem\u003eJ. Comput. Chem.\u003c/em\u003e \u003cstrong\u003e23\u003c/strong\u003e, 1623\u0026ndash;1641 (2002).\u003c/li\u003e\n\u003cli\u003ev. 2.0.1.2 OpenEye Scientific Software Santa Fe, NM, H. eyesopen. co. QUACPAC.\u003c/li\u003e\n\u003cli\u003eHawkins, P. C. D., Skillman, A. G. \u0026amp; Nicholls, A. Comparison of shape-matching and docking as virtual screening tools. \u003cem\u003eJ. Med. Chem.\u003c/em\u003e \u003cstrong\u003e50\u003c/strong\u003e, 74\u0026ndash;82 (2007).\u003c/li\u003e\n\u003cli\u003eNeves, B. J. \u003cem\u003eet al.\u003c/em\u003e Discovery of New Anti-Schistosomal Hits by Integration of QSAR-Based Virtual Screening and High Content Screening. \u003cem\u003eJ. Med. Chem.\u003c/em\u003e \u003cstrong\u003e59\u003c/strong\u003e, 7075\u0026ndash;7088 (2016).\u003c/li\u003e\n\u003cli\u003eHuang, Z. \u0026amp; Wong, C. F. Inexpensive Method for Selecting Receptor Structures for Virtual Screening. \u003cem\u003eJ. Chem. Inf. Model.\u003c/em\u003e \u003cstrong\u003e56\u003c/strong\u003e, 21\u0026ndash;34 (2016).\u003c/li\u003e\n\u003cli\u003ePearlman, D. A. \u0026amp; Charifson, P. S. Improved scoring of ligand-protein interactions using OWFEG free energy grids. \u003cem\u003eJ. Med. Chem.\u003c/em\u003e \u003cstrong\u003e44\u003c/strong\u003e, 502\u0026ndash;511 (2001).\u003c/li\u003e\n\u003cli\u003eHalgren, T. A. \u003cem\u003eet al.\u003c/em\u003e Glide: A New Approach for Rapid, Accurate Docking and Scoring. 2. Enrichment Factors in Database Screening. \u003cem\u003eJ. Med. Chem.\u003c/em\u003e \u003cstrong\u003e47\u003c/strong\u003e, 1750\u0026ndash;1759 (2004).\u003c/li\u003e\n\u003cli\u003eMousnier, A. \u003cem\u003eet al.\u003c/em\u003e Fragment-derived inhibitors of human N-myristoyltransferase block capsid assembly and replication of the common cold virus. \u003cem\u003eNat. Chem.\u003c/em\u003e \u003cstrong\u003e10\u003c/strong\u003e, 599\u0026ndash;606 (2018).\u003c/li\u003e\n\u003cli\u003eMadhavi Sastry, G., Adzhigirey, M., Day, T., Annabhimoju, R. \u0026amp; Sherman, W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. \u003cem\u003eJ. Comput. Aided. Mol. Des.\u003c/em\u003e \u003cstrong\u003e27\u003c/strong\u003e, 221\u0026ndash;234 (2013).\u003c/li\u003e\n\u003cli\u003eShelley, J. C. \u003cem\u003eet al.\u003c/em\u003e Epik: A software program for pKa prediction and protonation state generation for drug-like molecules. \u003cem\u003eJ. Comput. Aided. Mol. Des.\u003c/em\u003e \u003cstrong\u003e21\u003c/strong\u003e, 681\u0026ndash;691 (2007).\u003c/li\u003e\n\u003cli\u003eGreenwood, J. R., Calkins, D., Sullivan, A. P. \u0026amp; Shelley, J. C. Towards the comprehensive, rapid, and accurate prediction of the favorable tautomeric states of drug-like molecules in aqueous solution. \u003cem\u003eJ. Comput. Aided. Mol. Des.\u003c/em\u003e \u003cstrong\u003e24\u003c/strong\u003e, 591\u0026ndash;604 (2010).\u003c/li\u003e\n\u003cli\u003eJorgensen, W. L. \u0026amp; Tirado-Rives, J. The OPLS Potential Functions for Proteins. Energy Minimizations for Crystals of Cyclic Peptides and Crambin. \u003cem\u003eAnnu. Rev. Biophys. Bioeng\u003c/em\u003e \u003cstrong\u003e110\u003c/strong\u003e, 411 (1988).\u003c/li\u003e\n\u003cli\u003eShivakumar, D., Harder, E., Damm, W., Friesner, R. A. \u0026amp; Sherman, W. Improving the prediction of absolute solvation free energies using the next generation opls force field. \u003cem\u003eJ. Chem. Theory Comput.\u003c/em\u003e \u003cstrong\u003e8\u003c/strong\u003e, 2553\u0026ndash;2558 (2012).\u003c/li\u003e\n\u003cli\u003eFriesner, R. A. \u003cem\u003eet al.\u003c/em\u003e Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy. \u003cem\u003eJ. Med. Chem.\u003c/em\u003e \u003cstrong\u003e47\u003c/strong\u003e, 1739\u0026ndash;1749 (2004).\u003c/li\u003e\n\u003cli\u003eRepasky, M. P. \u003cem\u003eet al.\u003c/em\u003e Docking performance of the glide program as evaluated on the Astex and DUD datasets: A complete set of glide SP results and selected results for a new scoring function integrating WaterMap and glide. \u003cem\u003eJ. Comput. Aided. Mol. Des.\u003c/em\u003e \u003cstrong\u003e26\u003c/strong\u003e, 787\u0026ndash;799 (2012).\u003c/li\u003e\n\u003cli\u003eBerthold, M. R. \u003cem\u003eet al.\u003c/em\u003e KNIME: The Konstanz information miner. in \u003cem\u003eStudies in Classification, Data Analysis, and Knowledge Organization\u003c/em\u003e 319\u0026ndash;326 (Springer, Berlin, Heidelberg, 2008).\u003c/li\u003e\n\u003cli\u003eLi, J. \u003cem\u003eet al.\u003c/em\u003e The VSGB 2.0 model: A next generation energy model for high resolution protein structure modeling. \u003cem\u003eProteins Struct. Funct. Bioinforma.\u003c/em\u003e \u003cstrong\u003e79\u003c/strong\u003e, 2794\u0026ndash;2812 (2011).\u003c/li\u003e\n\u003cli\u003eBorrelli, K. W., Cossins, B. \u0026amp; Guallar, V. Exploring Hierarchical Refinement Techniques for Induced Fit Docking with Protein and Ligand Flexibility. \u003cem\u003eJ Comput Chem\u003c/em\u003e \u003cstrong\u003e31\u003c/strong\u003e, 1224\u0026ndash;1235 (2010).\u003c/li\u003e\n\u003cli\u003eCappel, D. \u003cem\u003eet al.\u003c/em\u003e Relative Binding Free Energy Calculations Applied to Protein Homology Models. \u003cem\u003eJ. Chem. Inf. Model.\u003c/em\u003e \u003cstrong\u003e56\u003c/strong\u003e, 2388\u0026ndash;2400 (2016).\u003c/li\u003e\n\u003cli\u003eNeves, B. J. \u003cem\u003eet al.\u003c/em\u003e Deep Learning-driven research for drug discovery: Tackling malaria. \u003cem\u003ePLoS Comput. Biol.\u003c/em\u003e \u003cstrong\u003e16\u003c/strong\u003e, (2020).\u003c/li\u003e\n\u003cli\u003eSander, T., Freyss, J., Von Korff, M. \u0026amp; Rufener, C. DataWarrior: An open-source program for chemistry aware data visualization and analysis. \u003cem\u003eJ. Chem. Inf. Model.\u003c/em\u003e \u003cstrong\u003e55\u003c/strong\u003e, 460\u0026ndash;473 (2015).\u003c/li\u003e\n\u003cli\u003eDaina, A., Michielin, O. \u0026amp; Zoete, V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. \u003cem\u003eSci. Rep.\u003c/em\u003e \u003cstrong\u003e7\u003c/strong\u003e, 1\u0026ndash;13 (2017).\u003c/li\u003e\n\u003cli\u003eBowers, K. J. \u003cem\u003eet al.\u003c/em\u003e Scalable Algorithms for Molecular Dynamics Simulations on Commodity Clusters. \u003cem\u003eSC \u0026rsquo;06 Proc. 2006 ACM/IEEE Conf. Supercomput.\u003c/em\u003e 43\u0026ndash;43 (2007) doi:10.1109/SC.2006.54.\u003c/li\u003e\n\u003cli\u003eJorgensen, W. L. Transferable Intermolecular Potential Functions for Water, Alcohols, and Ethers. Application to Liquid Water. \u003cem\u003eJ. Am. Chem. Soc.\u003c/em\u003e \u003cstrong\u003e103\u003c/strong\u003e, 335\u0026ndash;340 (1981).\u003c/li\u003e\n\u003cli\u003eJorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W. \u0026amp; Klein, M. L. Comparison of simple potential functions for simulating liquid water. \u003cem\u003eJ. Chem. Phys.\u003c/em\u003e \u003cstrong\u003e79\u003c/strong\u003e, 926\u0026ndash;935 (1983).\u003c/li\u003e\n\u003cli\u003eLu, C. \u003cem\u003eet al.\u003c/em\u003e OPLS4: Improving force field accuracy on challenging regimes of chemical space. \u003cem\u003eJ. Chem. Theory Comput.\u003c/em\u003e \u003cstrong\u003e17\u003c/strong\u003e, 4291\u0026ndash;4300 (2021).\u003c/li\u003e\n\u003cli\u003eMartyna, G. J., Klein, M. L. \u0026amp; Tuckerman, M. Nos\u0026eacute;-Hoover chains: The canonical ensemble via continuous dynamics. \u003cem\u003eJ. Chem. Phys.\u003c/em\u003e \u003cstrong\u003e97\u003c/strong\u003e, 2635\u0026ndash;2643 (1992).\u003c/li\u003e\n\u003cli\u003eMartyna, G. J., Tobias, D. J. \u0026amp; Klein, M. L. Constant pressure molecular dynamics algorithms. \u003cem\u003eJ. Chem. Phys.\u003c/em\u003e \u003cstrong\u003e101\u003c/strong\u003e, 4177\u0026ndash;4189 (1994).\u003c/li\u003e\n\u003cli\u003eBilsland, E. \u003cem\u003eet al.\u003c/em\u003e Functional expression of parasite drug targets and their human orthologs in yeast. \u003cem\u003ePLoS Negl. Trop. Dis.\u003c/em\u003e \u003cstrong\u003e5\u003c/strong\u003e, (2011).\u003c/li\u003e\n\u003cli\u003eFernandez-Ricaud, L., Kourtchenko, O., Zackrisson, M., Warringer, J. \u0026amp; Blomberg, A. PRECOG: A tool for automated extraction and visualization of fitness components in microbial growth phenomics. \u003cem\u003eBMC Bioinformatics\u003c/em\u003e \u003cstrong\u003e17\u003c/strong\u003e, 1\u0026ndash;15 (2016).\u003c/li\u003e\n\u003cli\u003eScherr, C., Baumgartner, S., Spranger, J. \u0026amp; Simon, M. Effects of Potentised Substances on Growth Kinetics of Saccharomyces cerevisiae and Schizosaccharomyces pombe. \u003cem\u003eComplement. Med. Res.\u003c/em\u003e \u003cstrong\u003e13\u003c/strong\u003e, 298\u0026ndash;306 (2006).\u003c/li\u003e\n\u003cli\u003eTrager, W. \u0026amp; Jensen, J. B. Human malaria parasites in continuous culture. \u003cem\u003eScience\u003c/em\u003e \u003cstrong\u003e193\u003c/strong\u003e, 673\u0026ndash;5 (1976).\u003c/li\u003e\n\u003cli\u003eSmilkstein, M., Sriwilaijaroen, N., Kelly, J. X., Wilairat, P. \u0026amp; Riscoe, M. Simple and Inexpensive Fluorescence-Based Technique for High-Throughput Antimalarial Drug Screening. \u003cem\u003eAntimicrob. Agents Chemother.\u003c/em\u003e \u003cstrong\u003e48\u003c/strong\u003e, 1803\u0026ndash;1806 (2004).\u003c/li\u003e\n\u003cli\u003eLeidenberger, M., Voigtl\u0026auml;nder, C., Simon, N. \u0026amp; Kappes, B. SYBR\u0026reg; green I-based fluorescence assay to assess cell viability of malaria parasites for routine use in compound screening. \u003cem\u003eMethods Mol. Biol.\u003c/em\u003e \u003cstrong\u003e1601\u003c/strong\u003e, 97\u0026ndash;110 (2017).\u003c/li\u003e\n\u003cli\u003eWang, C., Qin, X., Huang, B., He, F. \u0026amp; Zeng, C. Hemolysis of human erythrocytes induced by melamine-cyanurate complex. \u003cem\u003eBiochem. Biophys. Res. Commun.\u003c/em\u003e \u003cstrong\u003e402\u003c/strong\u003e, 773\u0026ndash;777 (2010).\u003c/li\u003e\n\u003cli\u003eKumar, P., Nagarajan, A. \u0026amp; Uchil, P. D. Analysis of Cell Viability by the MTT Assay. \u003cem\u003eCold Spring Harb. Protoc.\u003c/em\u003e \u003cstrong\u003e2018\u003c/strong\u003e, pdb.prot095505 (2018).\u003c/li\u003e\n\u003cli\u003eGoncalves, V. \u003cem\u003eet al.\u003c/em\u003e A fluorescence-based assay for N-myristoyltransferase activity. \u003cem\u003eAnal. Biochem.\u003c/em\u003e \u003cstrong\u003e421\u003c/strong\u003e, 342\u0026ndash;344 (2012).\u003c/li\u003e\n\u003c/ol\u003e"},{"header":"Tables","content":"\u003cp\u003eTable 2 is available in the Supplementary Files section.\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"nature-portfolio","isNatureJournal":true,"hasQc":false,"allowDirectSubmit":false,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"","title":"Nature Portfolio","twitterHandle":"","acdcEnabled":false,"dfaEnabled":false,"editorialSystem":"ejp","reportingPortfolio":"","inReviewEnabled":true,"inReviewRevisionsEnabled":false},"keywords":"","lastPublishedDoi":"10.21203/rs.3.rs-3963523/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-3963523/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eMalaria remains a significant public health challenge, with \u003cem\u003ePlasmodium vivax\u003c/em\u003e being the species responsible for the most prevalent form of the disease. Given the limited therapeutic options available, the search for new antimalarials against \u003cem\u003eP. vivax\u003c/em\u003e is urgent. This study aims to identify new inhibitors for \u003cem\u003eP. vivax N\u003c/em\u003e-myristoyltransferase (PvNMT), an essential drug target against malaria. Through a validated virtual screening campaign, we prioritized 23 candidates for further testing. In the yeast NMT system, seven compounds exhibit a potential inhibitor phenotype. \u003cem\u003eIn vitro\u003c/em\u003e antimalarial phenotypic assays confirmed the activity of four candidates while demonstrating an absence of cytotoxicity. Enzymatic assays reveal LabMol-394 as the most promising inhibitor, displaying selectivity against the parasite and a strong correlation within the yeast system. Furthermore, molecular dynamics simulations shed some light into its binding mode. This study constitutes a substantial contribution to the exploration of a selective quinoline scaffold and provides valuable insights into the development of new antimalarial candidates.\u003c/p\u003e","manuscriptTitle":"Selective Bias Virtual Screening for Discovery of Promising Antimalarial Candidates targeting Plasmodium N-Myristoyltransferase","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-02-20 09:30:36","doi":"10.21203/rs.3.rs-3963523/v1","editorialEvents":[],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"communications-chemistry","isNatureJournal":true,"hasQc":false,"allowDirectSubmit":false,"externalIdentity":"commschem","sideBox":"Learn more about [Communications Chemistry](http://www.nature.com/commschem/)","snPcode":"","submissionUrl":"","title":"Communications Chemistry","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"ejp","reportingPortfolio":"Communications Series","inReviewEnabled":true,"inReviewRevisionsEnabled":false}}],"origin":"","ownerIdentity":"0408b429-c782-4533-a94c-0319f2842a1e","owner":[],"postedDate":"February 20th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"under-review","subjectAreas":[{"id":28833009,"name":"Biological sciences/Drug discovery/Medicinal chemistry/Structure-based drug design"},{"id":28833010,"name":"Biological sciences/Chemical biology/Computational chemistry"}],"tags":[],"updatedAt":"2024-03-14T09:50:31+00:00","versionOfRecord":[],"versionCreatedAt":"2024-02-20 09:30:36","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-3963523","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-3963523","identity":"rs-3963523","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}